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1. Introduction
1.1. The Pulmonary Surfactant
Pulmonary surfactant, which is also known as the “surface active agent”, is a
complex mixture of lipids and proteins and primarily serves to reduce the surface
tension at the air-water interphase, thereby promoting expansion of the lung
during inspiration and preventing lung collapse during end-expiration [1]. It was
first studied by a Swedish physiologist, Kurt von Neergard in 1929, who claimed
the existence of a surface tension-reducing factor in the alveolar compartment
[2]. Later, discovery of the low surface tension in lungs was made in 1955 by
Pattle [3] and Clements [4] independently. A correlation between lack of surface
active material and Infant Respiratory Distress Syndrome (IRDS) was already
established during early years of surfactant discovery [5]. Further studies
emerged and isolation of this surface active substance led to the learning of its
chemical composition as a phospholipid-rich, membrane-like, lipoprotein
complex.
1.1.1. Synthesis, composition and secretion of pulmonary surfactant
Type-II alveolar cells are cuboidal epithelial cells. They coexist with the much
thinner type-I cell and can synthesize and secrete pulmonary surfactant. Clara
cells in the respiratory bronchioles manufacture at least some components of
pulmonary surfactant [6]. Lipids account for about 90% of the surfactant and are,
again, composed to roughly 90% by the amphiphilic phospholipids, the working
principle of surface-activity. Surfactant proteins (SP–A thorough –D) and a small
amount of plasma proteins account for the remaining 10% of pulmonary
surfactant (Fig.1) [7-11]. This composition is normally constant in all mammalian
species. Bronchoalveolar lavage (BAL) has been the main source to study the
surfactant composition. The phospholipid composition in different surfactant
subfractions is similar [12-14], with a high variability of protein composition [15,
16], suggesting the prominent influence of surfactant proteins on structure and
function of different surfactant fractions.
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Some lipid components of surfactant are taken up by alveolar epithelial cells type
II (AECII) from the blood stream and some of them are produced at the
endoplasmic reticulum of the AECII [17]. Some lipids are produced and fed to the
AECII by pulmonary lipofibroblasts. These lipofibroblasts are found next to AECII
in the pulmonary interstitium and are characterized by neutral lipid inclusions
wrapped in adipocyte differentiation related protein, which mediates the uptake
and trafficking of lipid from the lipofibroblast to the AECII for surfactant
phospholipid synthesis and protects the alveolar acinus against oxidant injury
[18, 19].
AECII uses the lysosomal compartment and secretory pathway to process the
lipids and the four apoproteins, all of which undergo substantial post-translational
modifications, and to finally assemble the mature surfactant in lamellar bodies
[6]. These are about 1µm diameter, consisting of concentric rings of proteins and
lipids. About 10% of the material present in the lamellar bodies is secreted per
hour by a normal lung. Secretion of surfactant occurs by constitutive exocytosis.
Freed from the confinement of the lamellar body and based on pH changes, the
surfactant then undergoes structural changes, taking the form of a mesh work
known as tubular myelin [11]. Surface-active surfactant containing surfactant
proteins A, B and C is secreted into the airways as large aggregate forms and
create a surfactant film with saturated phosphatidylcholine at air and water
interface on the alveolar surface. Squeeze and expansion of the surfactant film
by respiration disassociate surfactant lipid from surfactant proteins and become
small aggregate lipid vesicles containing only the lipids [6, 20]. Small surfactant
aggregates are not surface active and are preferably uptaken by AECII and
alveolar macrophages, which equally contribute towards surfactant uptake [20].
While surfactant uptake by alveolar macrophages is less dependent on the
physical form of surfactant or presence of surfactant proteins, its uptake by AECII
is more selective [6].
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Figure 1: Biochemical composition of pulmonary surfactant.
PC = phosphatidylcholine, PG = phosphatidylglycerol, PI = phosphatidylinositol, PE =
phosphatidylethanolamine, PS = phosphatidylserine, SPH = sphingomyelin
1.1.2. Surfactant lipids
Phospholipids form a predominant class of surfactant lipids, with a minor amount
(~10 – 20%) of neutral lipids. Among phospholipids, phosphatidylcholine
(PC~80%) is the major phospholipid class and contains an unusually high
amount of saturated fatty acids, mainly palmitic acid (16:0) [8, 11, 21-23]. About
50-70% of all PC molecules are dipalmitoylated (DPPC), thus representing the
most abundant surfactant component [6]. A high DPPC content is known to be an
absolute requirement for the high compressibility of the phospholipid film during
expiration and lowering of the surface tension to values near zero mN/m at end-
expiration [24]. The rest of the PC is composed of monoenoic and dienoic fatty
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acids at the 2-position, with only minor amounts of short chains or
polyunsaturated acyl groups [25, 26].
Phosphatidylglycerol (PG), which accounts for about 10% of total phospholipids,
is the second major surfactant phospholipid [8, 11]. Compared with other tissues,
PG is over-represented in lung surfactant. PG is characterized by a high content
(40-50%) of oleic acid (18:1) residues [25,27,28]. PG also contains a high
amount (20-50%) of palmitic acid, but the content of dipalmitoylated molecular
species is markedly lower. Because of its relative high content of unsaturated
fatty acids, PG alters the fluidity of DPPC and displays favourable adsorption
characteristics [29, 30].
Phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidyl-inositol
(PI), and sphingomyelin (Sph) are regulary found at low percentages. Their
precise function in surfactant remains, however, unclear [8, 11, 21-23].
Cholesterol is the major component (80-90%) of the neutral lipids, presumably
contributing to the biophysical surfactant activity by increasing fluidity and
improving film respreading. Mono, diacyl and cholesterol esters are found at low
percentages and are the minor components within this lipid fraction [31].
1.1.3. Surfactant proteins
Proteins account for approximately 10% of pulmonary surfactant dry weight.
Plasma proteins (mainly albumin) and secretory IgA make up about half of the
proteins and four apoproteins (SP-A,-B,-C and -D), make up the rest. SP-B and
SP-C are extremely hydrophobic low-molecular weight proteins, whereas SP-A
and SP-D are hydrophilic high-molecular weight glycoproteins [6].
1.1.3.1. The hydrophilic surfactant proteins, SP-A & SP-D
SP-A is the first identified surfactant protein and is the most abundant surfactant
protein by weight (3-4% of the surfactant mass). Both SP-A and SP-D are water
soluble and structurally similar, with an N-terminal collagen like domain, involved
in trimerization, and a C-type lectin domain in the C-terminus [6] that can bind a
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number of ligands in a calcium dependent fashion and based on specific
carbohydrates. Both “collectins” therefore significantly contribute to the
pulmonary innate host defense by acting as opsonins to coat bacteria and
viruses, thereby promoting phagocytosis by macrophages resident in the alveoli
[32], or by directly binding and aggregating viruses or bacteria. Although SP-A
had been suggested to exert a feedback control that limits surfactant secretion in
vitro, SP-A -/- mice show normal alveolar and tissue surfactant pool sizes,
suggesting that SP-A is not critical for regulation of surfactant homeostasis [33].
In contrast, SP-A -/- mice are prone to respiratory infection through a variety of
infectious agents and then undergo increased inflammation. SP-D -/- mice on the
other hand, show a strikingly different phenotype: These mice seem to have a
normal host defense, but develop progressive alveolar proteinosis and distal air
space dilation, associated with increased levels of tissue and macrophage-
associated metalloproteinases, macrophage derived oxidants and phospholipids
[34]. SP-D has therefore been suggested to control alveolar surfactant
homeostasis, most likely on the level of macrophage based phagocytosis [34-38].
1.1.3.2. The hydrophobic surfactant proteins, SP-B & SP-C
Being extremely hydrophobic, the SP-B and SP-C are soluble in organic solvents
like chloroform/ethanol or acetonitrile/water mixtures. Both these proteins are
synthesized and secreted by alveolar type-II cells and require specialized
intracellular processing events to reach maturity without being of harm to the
AECII [6].
Processing of SP-B occurs during its transit through the secretory pathway in
type-II pneumocytes. The SP-B preproprotein consists of 381 amino acids. A 23
amino acid signal peptide is located at the N-terminus of the proprotein, which
translocates SP-B into the lumen of endoplasmic reticulum. This signal peptide,
on translational cleavage, yields a proprotein which contains an N-terminal
propeptide (residues 24-200), a mature peptide of 79 amino acids (201-279), and
a C-terminal propeptide (residues 280-381). This C-terminal propeptide is
glycosylated on asparginine 311 [39]. This process, with the molecular weights of
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different processing intermediates is depicted in Fig. 2. Recent studies have led
to the understanding of the involvement of different enzymes in the post
translational processing of SP-B.
Figure 2. Processing, trafficking, and distribution of SP-B in type II pneumocytes and intra-
alveolar surfactant forms in human lungs: Post-translational processing of proSP-B to mature
SP-B is at least a three-step process with two distinct cleavages of the N-terminal propeptide and
one of the C-terminal propeptide. The processing of proSP-B to mature SP-B occurs between
Golgi vesicles and multi vesicular bodies. The colocalization of fragments of the N-terminal
propeptide (ocher dots) and mature SP-B (red dots) in multivesicular, composite, and some
lamellar bodies (LB) and the identification of a 5-kD fragment of the N-terminal propeptide in LB
provide evidence for the concept that the N-terminal propeptide of proSP-B is involved in the
transport of mature SP-B to LB. In human lungs, mature SP-B is involved in the structural
organization of LB by the formation of a projection core. Mature dimeric SP-B is secreted via the
LB in the intra-alveolar space, whereas SP-A (green dots) largely bypasses the LB. After
secretion, the outer membranes of unwinding LB become enriched with SP-A when tubular
myelin formation is initiated. Taken from Brasch et.al., American Journal of Respiratory, Cell
and Molecular Biology. Vol. 30, pp: 449-458, 2004.
The membrane bound, aspartyl protease Napsin A, and a cysteine protease
Cathepsin H, were reported to be responsible for the N-terminal cleavages of SP-
B [40]. A type-II cell specific aspartyl protease, Pepsinogen C was recently
identified as another necessary protease involved in SP-B processing [41].
Introduction 7
SP-C is a 21 kDa propeptide, synthesized by type-II pneumocytes and is
proteolytically processed to a 4.2 kDa dipalmitoylated protein. Previous studies
showed that the processing of the 21 kDa proSP-C through 16-, 7- and 6- kDa
intermediates, finally leading to mature SP-C is a four-step process, requiring
atleast two distinct cleavages of the C-terminal propeptide followed by atleast two
cleavages of the N-terminal propeptide (Fig.3). Cathepsin H has been indicated
in the first N-terminal processing step of SP-C. Infact, this cysteine protease is
the only enzyme that is known to be involved in SP-C processing [42].
Figure 3. Model of intracellular processing of SP-C: SP-C is synthesized by type II
pneumocytes as a 21-kD propeptide (proSP-C) which is proteolytically processed to a 4.2-kD
dipalmitoylated protein on the route from its site of synthesis to the lamellar bodies. In vivo, the
proteolytic processing of the 21-kD proSP-C through 16-, 7-, and 6-kD proSP-C intermediates to
mature SP-C is a four-step process requiring at least two distinct cleavages of the C-terminal
propeptide followed by at least two cleavages of the N-terminal propeptide. In the human lung,
cathepsin H is involved in the first N-terminal processing steps of proSP-C in electron dense
multivesicular bodies of type II pneumocytes after. Taken from Brasch et.al., Am. J. Respir. Cell
Mol. Biol., Volume 26, Number 6, June 2002 659-670.
1.2. Disorders of the pulmonary surfactant system
Surfactant alterations and mutations in the surfactant protein encoding genes
have been implicated in several diseases. It has long been studied that shortage
of surface active material due to lung immaturity is the driving cause for the infant
respiratory distress syndrome (IRDS) [5]. Under these conditions the elevated
alveolar surface tension at the air-liquid interface in the lungs results in greatly
reduced compliance and impaired gas exchange. Since the implementation of
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transbronchial surfactant therapy, the lethality of this condition could be reduced
by 50% [43]. Persistent respiratory distress may also be found in term infants,
excluding immaturity of AECII as underlying reason. In some of these patients,
deficiency of SP-B has been established as a first genetic cause of lethal IRDS
[44], shedding light on its indispensable role in postnatal survival. Parallelly, SP-B
-/- mice showed normal respiratory efforts, but failed to inflate the lungs and
rapidly died due to severe respiratory failure. Furthermore, neither proSP-B nor
SP-B proteins were detected, no tubular myelin and lamellar bodies were found
in the lungs of these mice [45]. Interestingly, aberrant processing of SP-C was
detected, indicating the essential role of SP-B in proteolytic processing of SP-C
[46]. A similar phenotype has been encountered in infants and some few older
patients with mutations of the ABCA3 gene.
In adult patients, surfactant alterations have been implicated to contribute to the
Acute Respiratory Distress Syndrome (ARDS), where substantial changes in the
surfactant composition and inhibitory events, rather than a lack of surface active
material, similarly results in an increase in alveolar surface tension and thus
induction of ventilation-perfusion mismatch, arterial hypoxemia and respiratory
failure [47].
Alterations in the surfactant system have been also been implicated in the
development of interstitial lung diseases (ILD). All diffuse parenchymal lung
diseases (DPLD) caused by surfactant alterations are tabulated under the
section: “Genetically defined disorders that may end up in progressive lung
fibrosis”.
1.3. Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown
etiology. It is a devastating disease process, which is characterized by fibroblast
accumulation, excessive collagen deposition, matrix remodelling and distortion of
the alveolar architecture. The progressive decline in lung function and
impairment in gas exchange causes dyspnea during exercise, later at rest and
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enforces nasal oxygen therapy at final stages. In face of a lack of an effective
treatment, patients usually die 2-4 years after diagnosis [48]. On the histological
level, temporal and spatial heterogeneity exist, resulting in still regular appearing
septae adjacent to disease-defining areas such as fibroblastic foci, honeycomb
changes with dense fibrosis and hyperplastic epithelium (Fig.4).
Figure 4. Idiopathic pulmonary fibrosis. H&E staining of lung tissue from a human
patient with IPF showing A) heterogenous pattern, with still regular appearing septae
adjacent to areas of dense fibrosis and honey combing, B) typical fibroblast foci and
cellular infiltration.
The pathogenesis of this incurable, chronic respiratory disease remains
unknown. However, two theories have been proposed for the development of
IPF. 1) The (older) inflammatory hypothesis and 2) The (more recent) alveolar
epithelial cell injury hypothesis.
1) The older hypothesis suggested that IPF results from chronic inflammation in
response to a yet undefined stimulus, and, if left untreated, would lead to
progressive lung injury and ultimately fibrosis [48]. Such reasoning was based on
the obvious signs of inflammation on histological (lymphoplasmacellular
infiltrates), BAL (marked neutrophilic alveolitis) and radiographic (enlarged lymph
nodes, modest ground glass opacities) findings. However, anti-inflammatory
therapies largely failed to gain any meaningful clinical effect, thereby providing
BA
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evidence that the inflammation events encountered in IPF seem neither to play a
causative role nor do they seem to substantially contribute to the progression of
the disease.
2) According to a more recent hypothesis, IPF primarily results from an epithelial
injury, followed by a misguided wound healing. Failure to re-epithelialize the
injured alveolar epithelium perpetuates and induces proliferation of interstitial
fibroblasts, which then transform into myofibroblasts and produce excessive
amounts of extracellular matrix (ECM) which ultimately leads to fibrosis [49, 50].
In line with this notion, increased apoptosis of type-II pneumocytes has been
found in areas of remodelled regions replaced by fibrous tissue adjacent to ECM-
producing myofibroblasts and also frequently in regions of lung with intervening
normal or nearly normal alveoli [51, 52].
Pulmonary fibrosis may be a manifestation of various genetic disorders, which
are defined briefly in the following section.
1.4. Genetically defined disorders that may end up in
progressive lung fibrosis
1. Hermansky Pudlak Syndrome platelet degranulation disorder,
hypopigmentation, colitis, interstitial lung
disease.
2. Chediak-Higashi Syndrome platelet degranulation disorder,
hypopigmentation, severe immunodeficiency.
3. Griscelli Syndrome
(mutated Rab 27)
hypopigmentation, immunodeficiency,
normal platelet function.
4. Mutated ABCA 3 Infant respiratory distress syndrome, Interstitial
lung disease.
5. Mutated SP-C Interstitial Lung Disease
6. Lipid storage diseases like
Nieman Pick disease
Interstitial Lung Disease
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1.5. Hermansky Pudlak Syndrome (HPS)
Hermansky-Pudlak syndrome (HPS) dates back to 1959, when two
Czechoslovakian physicists, F. Hermansky and P. Pudlak first defined the
syndrome as occulocutaneous albinism, associated with hemorrhagic diathesis
and pigmented macrophages in the bone marrow of two unrelated albinos. They
found that unusual reticuloendothelial cells in the bone marrow were packed with
blackish or greenish blue granules, a histochemical study of which revealed their
lipid nature [53]. Later on, several clinical case reports revealed that HPS is a
group of autosomal recessive disorders, which share the clinical findings of
occulocutaneous albinism, platelet storage pool deficiency, ceroid lipofuscinosis
and an early death caused by severe fibrotic lung disease [54 - 57]. The cellular
bases of these serious complications are unclear, but they seem to correlate with
the defects in the lysosome related organelles (LROs). Thus, the study that
started to analyze bleeding disorders has evolved into a much more complex
investigation, thereby becoming a subject of interest not only to clinicians, but
also to geneticists and cell biologists.
Mutations in the HPS gene are mostly prevalent in northwest Puerto Rico, and
are estimated to occur in about 1 in 1,800 persons, with a carrier frequency of 1
in 21 persons [58 - 60], proving that this is the home for largest group of known
HPS patients. However, some sporadic cases have been described in a variety
of backgrounds from Mexico, Holland, Sri Lanka and Japan and many patients
have been identified in the United States [61, 62]. It is otherwise an extremely
rare disease, occurring with a prevalence of 1 in 500,000 - 1,000,000 persons
[63, 64]. How the HPS mutations came to originate in Puerto Rico is unknown.
There are 7 known HPS genes in humans [63 – 70] and at least 16 HPS genes
causing the HPS-mutant phenotype in the mouse have been identified so far [69,
71 – 74]. These genes encode the following known proteins involved in vesicle
trafficking 1) the nine novel BLOCs (Biogenesis of Lysosome Related Organelle
Complexes), 2) the Adaptor Protein (AP)-3 and 3) the Vacuolar Protein Sorting
Complex (VPS) 33a (see Fig.5). Their sequences offer few clues to their
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functions or to the mechanisms by which they orchestrate the biogenesis and
trafficking of LROs (Lysosome Related Organelles). Apart from effecting the
different LROs, these genes control a wide range of physiological processes like
immune recognition, neuronal functions and lung surfactant trafficking [75].
Figure 5: HPS proteins in vesicle trafficking. HPS proteins act in the endocytic pathway to
affect the synthesis of a variety of lysosome-related organelles. The Ap3b1, Ap3d and Vps33a
proteins function in both lower and higher eukaryotes while the nine novel proteins of BLOC-1 –
BLOC-3 are found only in higher eukaryotes. For simplicity, these complexes are depicted as
participating only in the synthesis of lysosomes, though they are involved in the synthesis of
other lysosome-related organelles in higher organisms. The exact subcellular sites of action of
most HPS proteins are uncertain. While they are depicted here as acting between the trans-
Golgi network(TGN) and endosomes/MVB’s (Multi Vesicular Bodies), it is possible that they act
at other subcellular sites. Taken from Li.et.al., BioEssays 26: 616-628, 2004.
1.5.1. The BLOC complex: The biogenesis of lysosome related organelle
complex (BLOC) has been extensively studied in several organisms and found to
be linked to the secretory and endocytic pathways for protein and lipid trafficking.
Most known genes that are mutated to cause HPS in patients and mouse models
encode polypeptides, belonging to the BLOCs-1, -2 and -3 complexes [76 – 81].
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Several HPS mouse mutants are mimics in coat colour. This helped in predicting
the protein products of these genes as components of common protein
complexes termed as BLOCs. For example, the HPS-7, HPS-8, pallidin, muted
and cappuccino mice have similar coat colours and belong to BLOC-1 complex
[82 – 85]. Likewise, HPS3, HPS5 and HPS6 mutants that belong to BLOC-2 are
highly similar in coat colour. Their gene products are also co-members of the
BLOC-2 protein complex [86, 87]. The HPS1 and HPS4 mutants are similarly
indistinguishable and their protein products are components of BLOC-3 complex
[88, 89]. While BLOC-1 complex interacts with the cytoskeleton [89], BLOC-3 has
been shown to function in fibroblasts to regulate the intracellular location of
lysosomes [91]. The three BLOCs have been found in soluble (cytosolic) forms
as well as associated to membranes as peripheral membrane proteins. The
identity of the membrane-bound compartment(s) to which BLOC-1 and -2
associate is unknown. On the other hand, BLOC-3 has been localized by
immuno - fluorescence and immunoelectron microscopy to tubulovesicular and
vesicular structures near the golgi complex (in pigmented and non pigmented
cells) as well as to the membrane of maturing melanosomes, providing proof of
the involvement of this protein in trafficking [92]. Several binding partners like
syntaxin 13, SNARE-25, VAMP-2, are described for BLOC-1; but only one
candidate was reported for BLOC-2 and none for BLOC-3 [73]. The molecular
mass of the complex has been estimated to range from ~ 130 to 150kDa up to
200kDa in melanoma-derived cell lines [92]. Different types of HPS proteins and
mice models belonging to this complex are described in detail in the coming
sections.
1.5.2. The AP-3 complex: The AP-3 is the only known HPS gene product,
whose structure and functions are well characterised. Adaptor proteins are
heterotetrameric complexes that facilitate cargo selection and coated vesicle
budding from different membrane compartments. Four such complexes have
been identified in mammals, AP-1 through 4. Of interest is the AP-3 complex,
which plays a prominent role in mediating cargo protein selection into transport
vesicles and trafficking those membrane proteins to lysosomes [93].
Introduction 14
Figure 6: Structure of AP-3: AP-3 is a heterodimer consisting of
two large subunits (β3A and δ), a medium subunit, (µ3) and a
small subunit (σ3). The β3A and δ subunits have three domains:
the head or core region the hydrophilic hinge region and the ear or
appendage region. The carboxy-terminal domains of the two large
subunits project as ‘ears’, connected to the ‘head’ of the complex
by flexible hinges. Taken from Di Petro et.al., Current Opinion in
Cell Biology 2001, 13:444–453.
AP-3 is structurally and functionally related to the AP-1, AP-2 and AP-4
complexes. The head or the core region (Fig.6) is responsible for protein-protein
interactions. Yeast two-hybrid experiments have shown that the δ subunit
interacts with the σ subunits, that the β subunits interact with the µ subunits and
that the two large subunits interact with each other. It plays a crucial role in
sorting specific membrane proteins and facilitating carrier vesicle formation at the
trans-golgi network. These vesicles are then targeted to their specific subcellular
destinations like the lysosomes and lysosome related organelles [94].
Two naturally occurring mouse mutants have been identified with mutations in
AP-3 subunits. The first is the mocha (mh) mouse, which has a null mutation in
the δ subunit of the complex, leading to severe neuronal abnormalities [95]. The
second one is the the pearl (pe) mouse, which has an effectively null mutation in
the ß3A subunit (HPS-2) [96].
BLOC-1 interacts physically and functionally with AP-3 to facilitate the trafficking
of a known AP-3 cargo, CD63 and of tyrosinase - related protein-1 (Tyrp1). This
study also showed that BLOC-1 also interacts with BLOC-2 to facilitate Tyrp1
trafficking by a mechanism being apparently independent of AP-3 function [97].
Although an interaction between BLOC-1, BLOC-2 and AP-3 has been
suggested in several investigations, there is no experimental evidence regarding
a direct interaction between BLOC-3 and AP-3.
AP-3 complex
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1.5.3. Hermansky - Pudlak Syndrome associated Interstitial Pneumonia
Severe pulmonary fibrosis, manifesting in the 3rd or 4th decade of life, has been
shown to be the most serious complication of the disease, accounting for
premature death in 50% of HPS patients, generally by the 5th decade [98]. HPS1
and HPS4 individuals are known to show a greater degree of lung involvement,
with an estimate of about 80% of HPS1 subtypes afflicted [99 – 101]. Studies
evaluating pulmonary disease in other subtypes are lacking, disabling any
interpretation on the development of pulmonary fibrosis in other subtypes.
Numerous investigations have shed light on pathologic features which
demonstrated patchy fibrosis, alveolar septa displaying florid proliferation of type-
II pneumocytes with characteristic foamy swelling / degeneration and lymphocytic
and histiocytic infiltration around honey combing (Fig.6). Histochemical
examination revealed an over accumulation of phospholipids and a weak
positivity for Surfactant Protein-A (SP-A) (Fig.7).
Figure 7. H&E staining of lung tissue section from a patient with HPSIP, showing A) Advanced
lung remodeling with fibrosis, typically without an easily characterized distribution. B)
Accumulation of foamy type II pneumocytes and alveolar histiocytes laden with ceroid, an
insoluble lipoprotein substance, which is distinctive for HPSIP. Taken from Pierson et.al.,
Respiration 2006;73:382–395.
An ultrastructural study of these enlarged type-II pneumocytes revealed giant
lamellar bodies that compressed the nucleus. Accumulation of surfactant, termed
as “giant lamellar body degeneration”, is a prominent finding. Occasionally,
A B
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cytoplasmic disruption, suggestive of cellular degeneration was encountered
(Fig.8) [57]. With the exception of these AECII specific features, the overall
histopathological pattern of HPSIP appears quite similar to the usual interstitial
pneumonia pattern usually observed in IPF.
Figure 8: Histochemical analysis of lung tissue from 2 HPSIP patients: A) & B) Depicted are
H&E stains of the two patients. Type II pneumocytes are shown with characteristic foamy swelling
/ degeneration, and some showing small vanishing nuclei. C) Acid hematin staining showing
numerous cytoplasmic globules positively stained (blue/black) for phospholipid. D)
Immunostaining for surfactant protein A showing relatively weak positivity. Taken from Nakatani
et.al., Virchows Arch (2000) 437:304–313.
The pathogenesis of HPSIP is poorly understood. It has however been
speculated that intracellular disruption of type II pneumocytes by ceroid could
trigger inflammation, cytokine production and fibroblast proliferation, ultimately
culminating in the development of fibrosis. Hence, it appeared more likely that
the alveolar epithelium is the driving force in HPSIP development. HPS mouse
models serve as invaluable tools, in order to further study the role of AECII in
driving the disease.
A B
C D
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Figure 9: Electron microscopy of type II pneumocytes showing giant lamellar bodies
constantly in fusion with each other in the cytoplasm. The complex multilamellar pattern suggests
the formation of the giant lamlellar body by fusion of smaller ones. Taken from Nakatani et.al.,
Virchows Arch (2000) 437:304–313.
1.5.4. Types of HPS and corresponding mouse models
Initially bred for their attractive coat colours, the HPS mice mutants phenocopy
their human counterparts with one exception; i.e. there are no reports till date
revealing sporadic development of pulmonary fibrosis in any of the HPS mice
models. However, several studies showed the development of progressive
pulmonary emphysema in some of the mono and double mutant mice. As
mentioned below, about 16 genes causing a HPS-like phenotype in mice have
been identified so far. 8 of these genes have disease relevance to human HPS
(see Table 1), a detailed description of which is as follows:
5 µm
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Table1: List of human and mouse HPS genes (Taken from a review by Juan
S.Bonifacino, Ann. N.Y. Acad. Sci., 2004, 1038: 103–114).
HPS type 1: The human HPS 1 gene is present on chromosome 10, comprising
20 exons. The gene was identified by positional cloning and encodes a novel,
ubiquitously expressed 700-residue protein, which displays no homology to any
protein of known function. More than 20 disease causing mutations have been
reported in HPS 1 gene, the most common being a 16 bp frame shift duplication
in exon 15 [73]. Pale ear strain (ep) is the corresponding mouse model and the
mouse sequence is 81% identical to human amino acid sequence and 89%
similar [73, 88]. Previous reports indicate that mutations in HPS 1 gene in
humans lead to the development of abnormal organelles in their melanocytes
and development of severe pulmonary fibrosis. HPS 1 mutant mice mimic the
human disease with the exception of the development of pulmonary fibrosis.
Biochemical characterization using specific antibodies revealed that the HPS 1
protein exists as both cytosolic and peripheral membrane protein in both,
humans and mice. It was reported to be associated with HPS4 protein in the
200kDa cytosolic BLOC-3 complex, with a minor proportion also found to be
membrane associated. The HPS 1 and the HPS 4 proteins were co-
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immunoprecipitated, but the yeast two-hybrid analysis revealed no direct binding
between them, suggesting the presence of at least one other subunit in the
complex [100].
HPS type 2: This subtype is very unique because it is the only HPS subtype,
whose product (AP-3) has been assigned to a definite function. A candidate gene
approach was followed to identify the gene responsible for HPS-2. The pearl (pe)
gene, designated AP3b1 and its human orthologue, ADTB3A, encode the β3A
subunit of the Adaptor Protein–3 sorting complex [96]. The gene encoding β3A
consists of 3968 bp comprising 27 exons. The HPS-2 mutation has a tandem
duplication of 793 bp at the cDNA level, originating from the corresponding
duplication at the genomic level. The genomic analysis revealed that the
mutation contains a tandem duplication of six entire exons (exons 18–23) and
associated introns. The identical duplicated units are linked by a unique junction
intron that retains the upstream 5.6 kb of the 3′ intron (intron 23) and downstream
1.6 kb of the 5′ intron (intron 17), which are separated by a 0.2-kb partial mouse
transposon (MT) [102]. Patients with HPS-2 can be distinguished from those of
the other forms by the presence of neutropenia and susceptibility to recurrent
respiratory illnesses. The pearl mice exhibits pigment dilution, prolonged
bleeding and impaired kidney and platelet lysosomal enzyme secretion.
Interestingly, the pearl strain was suggested also as a model for human
congenital stationary night blindness, as it exhibits a reduced sensitivity in the
dark-adapted state. The beta3A transcripts of pearl mice were significantly
decreased in quantity and produced a beta3A protein with a truncation of
130 amino acids of the C-terminus of the 1,105-amino acid subunit, making it
undetectable at the protein level. This suggests that the expression and function
of the beta3A protein are significantly affected in pearl mice tissues. Interestingly,
in the brain tissue as well as in the melanocyte cell line of pearl mice, the µ3
subunit levels were undetectable, while both δ3 and σ3 were detectable at
reduced levels. Moreover, immunoflourescence studies in pearl cells using δ-
subunit specific antibodies revealed diffuse cytoplasmic labeling unlike the typical
punctuate pattern in control cells, indicating that although δ subunit is present in
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pearl cells, it is unable to associate with membranes in the absence of the β3 and
/ or µ3 subunits [103].
HPS type 3: The cocoa strain (coa) is the murine model for HPS-3 [86]. The
HPS 3 gene contains 17 exons, encoding for a protein with 1002 amino acids,
with a molecular mass of 113 kDa and is ubiquitously expressed. In humans,
more than twenty patients with HPS-3 have been reported with eight mutations
described [101]. Most commonly, these patients are homozygous for a large
3904 bp deletion, encompassing the whole exon 1 with more than 2 kb of
upstream sequence and 600 bp of intron 1. HPS-3 is clinically mild both in
humans and mice and it has been shown that the cocoa mice do not have a
defect in basal levels of secretion of lysosomal enzymes, although immature
melanosomes were found in retinal pigment epithelium and choroid. The most
important observation is that the HPS3 protein is associated with the HPS5 and
HPS6 proteins in the multimeric protein complex, BLOC-2 [78].
HPS type 4: The mouse model for HPS-4 is the light ear strain (le). The gene
consists of 14 exons. The mouse light ear protein is predicted to have 671 amino
acids with a molecular mass of 72.7 kDa [89]. Two isoforms of RNA transcripts
are detectable in light ear tissue, 3.6 and 3.1 kb in size. Cell lysosomal activity
was shown to be elevated in a cell line from light ear mouse skin. Many patients
with HPS-4 were reported and 10 different mutations in the HPS-4 gene were
identified. Lung biopsy from a HPS-4 patient suffering from pulmonary fibrosis
revealed an increased number of type II pneumocytes with foamy cytoplasm [61].
There are however, no reports till date, exhibiting lung abnormalities in light ear
mice.
HPS type 5: The ruby eye-2 mouse strain (ru-2) is the model for HPS-5 [87]. The
HPS-5 gene is found on chromosome 11 in humans and on chromosome 7 in
mice. The gene has 23 exons and encodes for a protein length of 1129 amino
acids with a molecular mass of 127kDa in humans. In mice, the gene has an
open reading frame of 3381 bp with 23 exons, encoding a 1126 amino acid
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protein, with a molecular mass of 126.3 kDa. It shares 81% homology with
human sequence. Seven disease causing mutations in HPS-5 were identified
[104]. All patients had visual impairment and increased cholesterol levels. None
of them had shortness of breath and showed minimal to no impairment by
pulmonary function testing. On a biochemical level, the HPS-5 molecule was
reported to bind to the α3A integrin [105]. The ru-2 mice copy the human HPS-5
disease. In choroids, several multi-melanosomal bodies were observed, which is
unique to the ruby eye-2 and ruby mutants [101].
HPS type 6: Ruby eye (ru) is the mouse model for HPS-6. The human HPS-6
gene is found on chromosome 10 with a single exon and a protein length of 775
amino acids. The mouse HPS-6 gene is found on chromosome 19 [87], and is
similar to human gene, containing a single exon with a protein size of 88.8kDa. It
shares an 80% homology with the human HPS6 protein. Four allelic ruby eye
strains were reported, out of which two strains (ru, ru4j) have inframe deletion of 3
amino acids H187 to P189 and 22 amino acid deletion L65 to W86, respectively.
Reports indicate that HPS-6 patients showed typical occulocutaneous albinism,
but no pulmonary fibrosis. The ru mouse model mimics human disease with no
major pulmonary alterations, although decreased kidney lysosomal enzyme
secretion after testosterone treatment was reported [101].
HPS type 7: The gene that is defective in HPS-7 is DTNBP1 (Dysbindin) and
sandy strain (sdy) is the corresponding murine model. It encodes dysbindin
protein on chromosome 6 with 10 exons. The Dtnbp1 defective gene encodes a
51 kDa, 352 amino acid protein with a predicted coiled coil region. In sdy mice,
an inframe deletion from genomic nucleotides caused deletion of 52 residues
(119-172 amino acids) comprising exons 6 and 7 including the majority of the
predicted coiled coil region. Dysbindin was confirmed to be component of BLOC-
1, but the functional significance is not yet clear. Six non-disease causing
polymorphisms and a single mutation have been reported in human patients.
Patients showed occulocutaneous albinism, mild shortness of breath and
decreased lung compliance, but otherwise normal pulmonary function. Studies in
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sdy mice showed markedly abnormal melanosomes and decreased retinal
pigment, with little insight into the lung abnormalities [82].
HPS type 8: Defect in the BLOC1S3 has lead to the identification of HPS-8. The
reduced pigmentation (rp) mouse gene is its orthologue. The mouse gene is
found on chromosome 7 containing 2 exons encoding a 195 amino acid protein.
Studies showed that BLOS3 is a component of BLOC-1 when in the
phosphorylated form. Patients have been identified to have a homozygous
germline frameshift mutation. They showed incomplete occulocutaneous albinism
and mild platelet dysfunction with easy bruising, frequent epistaxis and prolonged
bleeding after surgery or child bearing, requiring blood transfusion in some
cases. The rp mouse was reported to have increased kidney lysosomal
glycosidase activities, increased bleeding times, decreased platelet dense
bodies, immature melanosomes, decreased melanin and abnormal intracellular
tyrosinase distribution [67].
Other important models of HPS: Attempts to create a mouse model that more
severely mimics the human HPS disease, resulted in the development of some
HPS double, triple and quadruple mutant mice. This was done by intercrossing
the different HPS mono mutant mice. Mouse model homozygously recessive for
both HPS1 and HPS2 (ep/pe) displayed pathologic findings similar to the human
HPS. Type II cells of these mice showed giant lamellar body degeneration with
intracellular organelles demonstrating florid foamy degeneration of surfactant
material aberrantly produced and secreted. A more recent study on these double
mutant mice showed that they exhibited developmentally increased tissue
phospholipid concentration from postnatal day-2 to postnatal day 70. This study
focused on very young HPS1/2 mice, which showed an increase in mature
hydrophobic surfactant proteins in lung tissue and decreased stimulated
secretion by type II cells isolated from these mice [106]. Another important model
is the pale ear – ruby eye (ep/ru or HPS 1/6) double mutant, which exhibited air
space enlargement and honeycomb structure at the age of about 2 years [106].
Prominent lung abnormalities were observed in many combinations of
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double/triple mutants, but sporadic development of lung fibrosis has yet not been
reported in any of the murine strains investigated. Noteworthy information is the
development of giant lamellar bodies with combinations of any BLOC with AP-3,
which was supported by the increased phospholipid concentrations in their
respective lung tissues [80].
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2. Aim of the study
It is now known that severe pulmonary fibrosis is found in some patients with
HPS (HPSIP) and that the occurrence of HPSIP then largely dictates a poor
prognosis. However, despite the fact that there are 16 different murine HPS
strains mimicking the human HPS gene defects there is, up to now, no report on
development of lung fibrosis in mice. Likewise, the underlying pathomechanistic
principle for development of HPSIP is yet not known. The aim of this study was
therefore to screen different murine HPS models (HPS1,2,6,1/2,1/6) for
development of lung fibrosis and to undertake genotype / phenotype correlations
with special emphasize on impaired lysosomal trafficking and the cellular
consequences of which in alveolar type II cells. For this purpose, the following
questions were addressed.
 Is pulmonary fibrosis, which is found in some patients with HPS, also
found in some murine forms of HPS, pending on the genotype?
 Does HPS result in impairment of lysosomal trafficking in alveolar type II
cells, thereby inducing defective surfactant metabolism? If yes, would
there be differences in dependency of the genotype?
 Does the extent of altered surfactant metabolism correlate with
phenotype?
 What would be the cellular consequences of such altered lysosomal
transport in the alveolar type II cells? Does the altered lysosomal transport
induce lysosomal or ER stress and cause apoptosis?
 Finally, as development of apoptosis was suggested to represent a key
event in Idiopathic Pulmonary Fibrosis, another ultimatively lethal
interstitial lung disease, would the extent of epithelial apoptosis in the
various HPS models correlate with the development of lung fibrosis?
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3. Materials
3.1. General materials
Manufacturer Products
Carl Roth, Karlsruhe, Germany. Tris, NaCl, Rotipherose, Sacharose,
APS, Glycine,Agarose, BSA.
Sigma Aldreich, Steinheim, Germany EDTA, Triton X-100, Tween20, β-
mercaptoethanol, DNase.
Fluka chemie, Buchs, Switzerland. Sodium deoxy cholate, TEMED,
Skimmed milk powder, Methanol,
Chloroform, Acetic acid.
Merck, Darmstadt, Germany. Sodium dodecyl sulphate, Perchloric
acid, Bromophenol blue, NaOH, HCl,
Ascorbic acid, KH2PO4, Na2HPO4,
KCl.
Amersham, Brunswick, Germany Hybond PVDF membrane, ECL
western blot detection system, ECL
hyperfilms.
Whatman GmbH, Dassel, Germany. Whatmann papers, 3mm.
Wak chemie, Steinbach, Germany. RNA Zol-B.
Applied Biosystems Random hexameres, RNase inhibitor
Fermentas dNTP mix.
GIBCO/Invitrogen, Germany. DMEM, RPMI, L-Glutamine, Pencillin/
Streptomycin.
PAA Laboratories GmbH, Marburg,
Germany.
FCS.
BD Biosciences, Belgium. Dispase.
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3.2. Materials for animal work
Manufacturer Products
Braun Melsungen, Germany Use and throw syringes and needles.
Beckton-Dickinson, Germany Tracheal cannulae, (Kanuele 26G)
Pfizer, Karlsruhe, Germany. Ketamin hydrochloride (100mg/ml)
(KetavetR)
Bayer, Leverkusen, Germany. Xylazinhyrochloride (RopumR)
Ethicon GmbH, Norderstedt,
Germany.
Surgical threads, non absorbable
Martin Medizintechnik, Germany. Surgical instruments.
3.3. Materials for histology
Manufacturer Products
Fischer scientific, Germany. Ethanol 70%, 95%, 99.6%,
Formaldehyde, alcohol free.
Carl Roth, Karlsruhe, Germany. Rotihisto (Xylolersatz), Xylol,
Haemalaun.
R. Langenbrinck, Teningen, Germany. Histologic glass slides.
Menzel, Braunschweig, Germany. Cover slips, 24 x 36 mm
Feather, Japan. Microtome blades.
Dako cytomation, Hamburg, Germany. Glycerol mounting medium.
Leica Microsystems, Nussloch,
Germany.
Automated microtome, flattening for
paraffin sections, tissue embedding
cassettes, cooling plate.
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3.4. Kits
Manufacturer Products
Zytomed systems, Berlin, Germany. Zytochem AP Fast red kit, broad
spectrum – for immunohistochemistry.
Roche, Germany. In situ cell death detection kit,
Flourescein.
Pierce, Germany. BCA protein assay kit.
Qiagen, Hilden, Germany. Omni transcript RT kit for Reverse
transcription.
Hot start taq DNA polymerase kit for
PCR.
DNeasy blood and tissue kit for genomi
DNA isolation.
3.5. List of primers
WT HPS1-forward 5’ AGCTAGAACACTGTCCAAAGATAGC 3’
WT HPS1-reverse 5’ GTATGAGAGAAGGCACTGGAAGAAG 3’
HPS1-forward 5’ AGCTAGAACACTGTCCAAAGATAGC 3’
HPS1-forward 5’ ATGTAAGAATAAAGCTTTGTCGCAG 3’
WT HPS6-forward 5’ ACATCCTGCTACACCATTGCCCC 3’
WT HPS6-reverse 5’ CATGTCCAGTAGTTCCAAGGTGGAG 3’
HPS6-forward 5’ CACCCACATCCTGCTACACCTTTTTG 3’
HPS6-reverse 5’ CATGTCCAGTAGTTCCAAGGTGGAG 3’
HPS2-forward 5’ GAAATGGGGCTGCACATAG 3’
HPS2-reverse 5’ GAACCCTCACACAGGACTCG 3’
Cathepsin D-forward 5’ GGTACCTGAGCCAGGACAC 3’
Cathepsin D-reverse 5’ CCGTGGTAGTACTTGGAGTC 3’
β – actin-forward 5’ CTACAGCTTCACCACCACAG 3’
β – actin-reverse 5’ CTCGTTGCCAATAGTGATGAC 3’
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3.6. List of antibodies
Name of the antibody Dilution Company
Rabbit X Human proSP-B 1:1000 (WB) Chemicon
Rabbit X Sheep mature SP-B 1:1000 (WB) Chemicon
Rabbit X Human proSP-C 1:1000
(WB,IH)
Chemicon
Rabbit X Human mature SP-C 1:100 (WB) Altana pharma
Rabbit X Mouse β-actin 1:5000 (WB) Abcam
Rabbit X Mouse CHOP 1:200 (WB) Santacruz
Goat X Mouse Cathepsin D 1:1000 (WB)
1: 50 (IH)
R&D systems
Rabbit X Human Cathepsin D 1:200 (IH) Abcam
Rabbit X Human Cleaved
Caspase-3
1:50 (IH) Trevigen
Rabbit X Mouse CHOP 1:50 (IH) Santacruz
Mouse X Human CHOP 1:50 (IH) Abcam
HRP conjugated secondary
antibodies (anti-rabbit or anti-
goat)
1:2000 (WB) Dako cytomation
Rat X Mouse CD16/32 15µl/10ml RPMI
(panning antibody
for AEC isolation)
BD Biosciences
Rat X Mouse CD44 15µl/10ml RPMI
(panning antibody
for AEC isolation)
BD Biosciences
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3.7. Equipment & software
Manufacturer & Type Products
Applied Biosystems, PCR system 2400 Thermocycler
Bio-rad, Trans-blot SD, semi dry
electrophoretic transfer blot
Transfer machine for Western blots.
Tecan Spectraflour plus; MTX lab
systems Inc.
ELISA plate reader.
Magellan Tecan Inc. Software for ELISA reader
AlphaInnotech, Alphaease. Gel biodoc for UV light .
Alphaease FC Software for densitometry.
Carl Zeiss Micro Imaging Inc. Mirax micro digital slide scanner with
viewer software, Light microscope.
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4. Methods
4.1. Animals
Breeding pairs of all HPS mono mutant mice, HPS1/6 double mutant mice were
bought from Jackson laboratories. Breeding pairs of HPS1/2 double mutant mice
were obtained from the lab of Dr. Richard Swank, Roswell park, Buffalo, NY. The
background strain for HPS1, HPS2, HPS6 and HPS1/2 mice was C57Bl/6J. The
HPS1/6 mice were on B6C3Fe background. All these mice were mated and
maintained in the central animal housing facility under SPF (specific pathogen
free) conditions. All HPS mice along with WT controls used in this study were
sacrificed at the age of 3 months and 9 months.
HPS mice can be generally identified by their different coat colours. Inspite of
this, all HPS mice were genotyped for the mutated gene with the primers
mentioned in the list of primers in ‘Materials’ section. Genomic DNA for this
purpose was isolated with DNeasy kit according to the manufacturer’s protocol.
All mice were tested periodically and were free of known viral and bacterial
pathogens. Mice were sacrificed by injecting an overdose of anesthesia (Ropum
solution - 2% of the injecting solution, 100mg/ml ketavet; a final volume of 100µl
per mouse). Thorax and abdomen were then disinfected with BraunolR. Each
mouse was then fixed, a small slit was made near abdomen, the skin and belly
were cut open upto the mentum. The diaphragm was carefully teared and the rib
and elbows were spread apart and fixed laterally. Within the ventral neck region,
trachea was seen covered with connective and muscle tissue which were
carefully teared apart without damaging the trachea. An incision was made in the
trachea with a blunt tweezer into which, a tube (braunuele) was inserted and
fixed. The left main bronchus was clamped and the right lung was washed
(lavaged) three times with 350µl 0.9% NaCl each time. The lavage was done with
same volume and in the same way for both HPS and control mice. This lavage
(broncho alveolar lavage or BAL) was collected in an eppendorf cup and
centrifuged for 10 minutes at 300xg, at 4oC. The supernatant was transferred to a
new vial and shock frozen in liquid Nitrogen. The clamp from the left main
bronchus was removed and fixed to the right main bronchus. The bronchus was
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cut distal from the clamp and the right lung was excised and shock frozen. Before
taking the left lung for histology, the lung was flushed to make it free from blood
via the right ventricle. Formalin fixation was achieved by filling the lung with 3.7%
Formaldehyde solution with a constant hydrostatic pressure of 20 cm H2O.
Following instillation the trachea was ligated, the lung was carefully removed and
transferred into a cup and covered with Formaldehyde solution. After overnight
incubation at 4°C, the lung was transferred into an embedding cassette, buffered
in PBS and stored at 4°C. This lung tissue was processed in a Vacuum-dryer for
dehydration and then embedded in paraffin. 3µm thin sections wee cut with a
microtome for further analysis.
4.2. Histology
4.2.1. Hematoxylin & Eosin staining: H&E staining is a charge-based, general
purpose stain, widely used for routine histological examination of tissue sections.
It is a two-stage stain for cells, in which hematoxylin is followed by a counter
stain of red eosin. The hematoxylin stains acidic molecules, which gives shades
of blue and eosin stains basic materials and gives shades of red, pink and
orange, thereby, staining the nuclei with a deep blue-black and the cytoplasm
with pink, respectively. The staining protocol is summarized as follows:
Staining time(minutes) Reagents
2x 10 Rotihistol
1 x 5 Rotihistol
2 x 5 Ethanol (absolute)
1 x 5 Ethanol (96%)
1 x 5 Ethanol (70%)
1 x 2 Aqua.dest
1 x 20 Hemalaun (acidic)
5 Running water
1 Ethanol (96%)
4 Eosin (alcoholic)
washing Aqua.dest
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4.2.2. Trichrome staining: A staining method utilizing a combination of
three different dyes to identify different cell or tissue elements. This method is
especially suitable for studying connective tissue. Nuclei are normally stained
blackish brown, cytoplasm is stained brick red, erythrocytes are stained
yellow / orange and mucous substances and collagen are stained in green.
Following is the protocol in a table format for trichrome staining.
2 x 2 Ethanol (96%)
1 x 5 Ethanol (99.6%)
1 x 5 Isopropyl alcohol (99.8%)
2 x 5 Rotihistol
1 x 5 Xylol
Mount with pertex, which is a xylol
based mounting medium.
Staining
time(minutes) Reagents
2 x 10 Rotihistol
2 x 5 Ethanol (absolute)
1 x 10 Weigert hematoxylin
1 x 5 Warm, running tap water
1 x 10 Ponceau acid fuschin solution
4-5x 1% acetic acid until nonspecific shades
are washed off.
1 x 5 Orange-G solution
4-5x Wash in 1% acetic acid
1 x 20 Light green solution
2 x 5 Ethanol (99.6%)
2 x 5 Rotihistol
1 x 5 Xylol
Mount with pertex.
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4.3. Western blot analysis
Homogenization of mice lungs: The right halves of the snap frozen lung
tissues were pulverized by mortar and pestle. The pulverized tissue was treated
with lysis buffer containing protease inhibitor. The ground tissue treated with lysis
buffer was incubated for about an hour on ice, followed by centrifugation at
13000 rpm at 4°C for 10 minutes. The supernatant was obtained and used for
protein concentration determination by Bicinchoninic acid (BCA) method.
Poly Acrylamide Gel Electrophoresis of protein (SDS-PAGE): Protein sample
from tissue extract was either non-reduced or reduced (by adding 10% β-
mercaptoethanol) and denatured by heating to 95°C for 10 min in 4 x loading
buffer, (5g SDS, 40ml glycerin, 25ml stacking gel buffer, 0.01g bromophenolblue
for a final volume of 100ml) and then cooled on ice immediately. The samples
were collected by brief centrifugation and then loaded on self casted
polyacrylamide gels. In the presence of 1x electrode buffer (10x buffer: 25mM
tris, 192mM glycin, 0.1%SDS) the electrophoresis was performed with 15mA
constant and the gel was run till the bromophenol blue reached the bottom of the
resolving gel. Then, the gel was used for Western-blot analysis.
Lysis buffer pH 7.4 Final concentration
Tris 50mM
NaCl 150mM
EDTA 5mM
Triton X-100 1%
0.5% Sodium deoxycholat 0.5%
PMSF 1mM
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Electro blotting of immobilized proteins: The separated proteins on the SDS-
polyacrylamide gel were transferred to a polyvinylidene fluoride (PVDF)
membrane by electro blotting. The PVDF membrane was activated by methanol
before used. The transfer equipment was prepared in the following way: two
layers of Whatmann 3mM filter paper washed with transfer buffer (20mM tris,
150mM glycin, 20% methanol) followed by activated PVDF membrane washed
with transfer buffer were placed onto the electro blotting chamber. On the PVDF
membrane, the gel and the other two layers of filter paper washed with transfer
buffer were placed. Electro blotting was performed at constant current (2mA /
cm2) for approximately 90 min.
Immunological determination of immobilized proteins: The membrane was
blocked with 5% non fat dry milk in 1% TBST buffer at room temperature for 1h
followed by incubation with primary antibody at 4°C overnight. After washing with
1 x TBST three times for 20 min each, the membrane was incubated with the
respective secondary antibody at room temperature for 2 h followed by three
SDS PAGE Resolving gel buffer Stacking gel buffer
Rotipherose 3.3ml 5ml 1.33ml
Dist.H2O 3.2ml 1.53ml 6.57ml
10%SDS 100µl 100µl 100µl
Resolvinggel buffer 3.33ml 3.33ml -----
Stacking gel buffer ----- ----- 2ml
10%APS 50µl 50µl 100µl
TEMED 10µl 10µl 10µl
 (1.125M Tris/HCl, pH8.8,
30%sacharose)  
10% 15%
(0.625M Tris/HCl, pH6.8)
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times washing with 1 x TBST buffer for 20 min each (10x buffer: 500mM tris,
500mM NaCl, 0.1% tween 20). The protein bands were detected by ECL
(Enhanced Chemi-luminescence) treatment, followed by exposure of the
membrane to ECL films in dark. Bands on the film were then visualized by
dipping them in developing and fixing solutions.
4.4. Phospholipid analysis
Phospholipids were extracted according to the classical Bligh & Dyer method.
25µl of lung homogenate was used as a starting material. The volume was made
upto 800µl with 0.9% NaCl. Phospholipids were isolated by adding 3ml Methanol
: Chloroform (2:1) followed by a 30 minutes incubation at RT. The phospholipids
were resolved by adding chloroform and methanol, 1ml each and centrifugation
was performed at 2500xg, for 10 minutes at 4oC. Phase separation was
observed and the upper chloroform phase was pipetted into a new tube followed
by drying under liquid Nitrogen. Phosphate assay was performed by adding
200µl of perchloric acid into both standards and samples followed by cooking at
200oC for 1 hour. After cooling down the tubes to room temperature, 20µl
(114mg/ml) ascorbic acid and 1ml Ammonium Molybdate (4.6mM) were added
and allowed to develop colour at 60oC for 45 minutes. The tubes were cooled
down and the absorbance of each sample was measured at a wavelength of
698λ. The OD values were noted and the concentration of phosphate was
measured by means of a standard curve. Concentration of phospholipids was
calculated by the formula: µg PL / 1ml = [µg Phosphorous] x 734/31 x dilution
factor (734: molecular weight of DPPC, 31: molecular weight of Phosphorous).
The resultant values were normalized to 1 mg protein concentration of respective
samples before analysis.
4.5. Lipidomics
Lipids were quantified by electrospray ionization tandem mass spectrometry
(ESI-MS/MS) in positive ion mode as described previously (Brügger et al.,
Liebisch et al. 2004, Liebisch et al. 2006) (Tab. 1). Samples were quantified by
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direct flow injection analysis using the analytical setup described by Liebisch et
al. (Liebisch et al. 2004, Liebisch et al. 2006). A precursor ion scan of m/z 184
specific for phosphocholine containing lipids was used for phosphatidylcholine
(PC), sphingomyelin (SM) (Liebisch et al. 2004) and lysophosphatidylcholine
(LPC) (Liebisch et al. 2002). Neutral loss scans of m/z 141 and m/z 185 were
used for phosphatidylethanolamine (PE) and phosphatidylserine (PS),
respectively (Brügger et al.). PE-based plasmalogens were analyzed according
to the principles described by Zemski-Berry (2004). Phosphatidylglycerol was
analyzed using a neutral loss scan of m/z 189 of ammonium adduct ions
(Schwudke et al.). Ceramide was analyzed similar to a previously described
methodology (Liebisch et al. 1999) using N-heptadecanoyl-sphingosine as
internal standard. Free cholesterol (FC) and cholesteryl ester (CE) were
quantified using a fragment ion of m/z 369 after selective derivatization of FC
using acetyl chloride (Liebisch et al. 2006). Correction of isotopic overlap of lipid
species as well as data analysis by self programmed Excel Macros was
performed for all lipid classes according to the principles described previously
(Liebisch et al. 2004). Experiments concerning to lipidomic profiling were
performed by Dr. Gerhard Liebisch, Department of clinical chemistry, University
of Regensburg, Germany.
Lipid MS - unlabelled
Phosphatidylcholine – PC
Sphingomyelin - SPM ESI+, PIS m/z 184
Lyso-PC - LPC ESI+, PIS m/z 184
Phosphatidylethanolamine - PE ESI+, NL m/z 141
PE based Plasmalogens
ESI+, PIS m/z 364 (O-16:1)
PIS m/z 392 (O-18:1)
PIS m/z 390 (O-18:2)
Phosphatidylglycerol - PG ESI+, NL m/z 189
Phosphatidylserine - PS ESI+, NL m/z 185
Ceramide (d18:1) - Cer ESI+, PIS m/z 264
Cholesterol/Cholesteryl ester – FC/CE ESI+, PIS m/z 369Derivatisation
Table.2: Methods established for direct flow injection analysis of lipids with and without stable
isotope labelling.
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4.6. Isolation of RNA from mice lungs
RNA was extracted from cells using guanidine thiocyanate-acid phenol (RNAzol
B, WAK-Chemie, Germany). RNA-Bee is a complete and ready-to-use reagent
for isolation of total RNA from samples of human, animal, plant, bacterial and
viral origin. A biological sample is homogenized or lysed in RNA-Bee and the
homogenate/lysate is separated into aqueous and organic phase by the addition
of chloroform. The subsequent centrifugation efficiently removes DNA and
proteins from the aqueous phase containing RNA. The non-degraded, pure RNA
is obtained from the aqueous phase by the isopropanol precipitation, washing
with ethanol and solubilized in an appropriate solution. Snap frozen lung tissue
was taken into a 15 ml falcon tube with 4ml RNAzol and homogenized on ice.
Thereafter, 400µl of chloroform was added with mixing. The solution was
incubated on ice for 30 min and centrifuged at 5000 rpm at 4°C for 45 min. The
upper phase (~1ml) containing RNA was collected in a new 2ml eppendorf cup.
The RNA was precipitated by addition of equal volume of isopropanol, incubating
at -20°C for 1 hour and centrifuging at 13,000 rpm at 4°C for 10 min. The RNA
pellet was washed once with 500µl 70% ethanol. The purified RNA was
centrifuged again for 10 min at 13,000 rpm and dried at room temperature for 10
min. Finally, the pellet was dissolved in appropriate volume of RNase free H2O.
After measuring the RNA concentration, the samples were stored at -80°C. To
determine the concentration and purity of the RNA, the extinction at 260 nm and
280 nm was measured. An OD of 1 at 260 nm corresponds to 40µg RNA/ml. The
ratio of the OD at 260 nm and at 280 nm is a measure of RNA purity. In a
protein-free solution the ratio OD260/OD280 is 2. Due to protein contaminations
this coefficient is usually lower. In the experiments of this study, it was between
1.7 and 2.
4.7. Preparation of cDNA from RNA probes
For the preparation of cDNA, 2µg RNA per sample was used. RNA was copied to
cDNA using reverse transcriptase (Qiagen, omnitranscript RT kit) with random
hexameres. 15µl of the following master mix was added to 2µg / 5µl RNA.
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The denatured RNA mixed with master solution was then subjected for cDNA
synthesis by incubating at room temperature for 15 minutes and then at 37oC for
1 hour.
4.8. Semi-quantitative RT PCR
The polymerase chain reaction (PCR) allows amplification of DNA fragments due
to repetitive cycles of DNA synthesis. The reaction uses two specific
oligonucleotides (primers), which hybridize to sense and antisense strands of the
template DNA fragment, four deoxyribonucleotide triphosphates (dNTP‘s) and a
heat-stable DNA polymerase. Each cycle consists of three reactions that take
place under different temperatures. First, the double-stranded DNA is converted
into its two single strands (denaturation at 94°C).
They function as templates for the synthesis of new DNA. Second, the reaction is
cooled (50-60°C) to allow the annealing (hybridization) of primers to the
10xBuffer 2µl
dNTPs 2µl
Randomhexameres 4µl
RNase-inhibitor 0.5µl
H2O 5.5µl
RT 1µl
PCR reaction per 25µl
10xBuffer 2.5µl
dNTPs 0.5µl
Forward primer 1µl
Reverse primer 1µl
H2O 17.75µl
Taq polymerase 0.25µl
cDNA 2µl
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complementary DNA strands. Third, DNA polymerase extends both DNA strands
at 72°C (DNA synthesis) starting from the primers. The PCR was performed in a
thermocycler, programmed as follows:
Activation of Hotstart Taq 94°C 20min
Denaturation 94°C 30sec
Annealing refer Table 3 30sec
Extension 72°C 1min
Cycles 30
Final Extension 72°C 10min
Table.3: Annealing temperatures of primers
After the amplification, PCR products (10 µl) were electrophoretically analyzed in
a 2% agarose gel with 0.2 µg /100 ml ethidium bromide.
4.9. Agarose gel electrophoresis
The DNA sample was mixed with loading buffer (0.01% bromophenol blue, 40%
glycerol, to a final volume with 10x TAE buffer) and loaded onto the 2% agarose
gel. The electrophoresis was performed for 45-60 min with 5 V/cm. The
negatively charged DNA migrated from the cathode (-) to the anode (+). To
visualize DNA, the gel was treated with ethidium bromide (0.5 µg/ml), which
intercalated between the bases of DNA double strands forming a complex
Primers for annealing temperature
HPS1 57oC
HPS2 59oC
HPS6 60oC
Cathepsin-D 55oC
Glucosylceramide synthase 57oC
β-actin 55 oC
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fluorescent under UV light. The size of amplified DNA was determined by a DNA
molecular weight standard. The agarose gel was visualized by flourChem 8900,
gel bio doc system.
4.10. Immunohistochemistry
Immunohistochemistry (IHC) is the localization of antigens in tissue sections by
the use of labeled antibody as specific reagents through antigen-antibody
interactions that are visualized by a marker such as fluorescent dye, enzyme,
radioactive element or colloidal gold. Since immunohistochemistry involves
specific antigen-antibody reaction, it has apparent advantages over other
traditionally used special enzyme staining techniques that identify only a limited
number of proteins, enzymes and tissue structures. There are numerous
immunohistochemistry methods that may be used to localize antigens. The
selection of a suitable method should be based on parameters such as the type
of specimen under investigation and the degree of sensitivity required. Mice
lungs were fixed in paraformaldehyde as described earlier and sections of 3µm
thickness were used for immunohistochemical analysis in this study. Sections
were deparaffinized at 60oC for 2 hours and then in xylene for 10 minutes. They
were then rehydrated in descending alcohol concentrations
(99.6%>96%>80%>70%>50%). Sections were washed in washing buffer (1x
PBS) to remove traces of ethanol. Antigen retrival was performed by detergent
method, using 0.4% Triton X-100 in 1xPBS (10x buffer: 80g NaCl, 29g
Na2HPO4x12.H20, 2g KCl, 2g KH2PO4, 1L final volume with d.H20, pH7.4).
Sections were immersed in this permeabilization buffer for 5 minutes and
washed. The AP fast red kit was used for further steps. The sections were
blocked for 10 minutes in the blocking solution followed by washing. Primary
antibody solutions were prepared in 3% BSA solution with respective dilutions. A
negative control was always used where primary antibody was omitted. Sections
were placed in a humid chamber and incubated with primary antibody overnight
at 4oC, followed by washing for 5 times. 50µl of biotinylated secondary antibody
was added to each section and incubated for 10 min at RT, followed by washing.
Methods 41
Few drops of enzyme conjugate (streptavidin / alkalic-phosphatase conjugate)
were added to each section with 10 min incubation at RT, followed by washing.
Fast red tablets were used as substrate which was freshly prepared by dissolving
one fast red tablet in one substrate buffer vial (naphtol-phosphate buffer). 50µl of
this substrate solution was given to each section and allowed to develop in the
dark, with constant monitoring for the pink colour development under light
microscope. Enough care was taken that all HPS sections, control sections and
negative control sections be treated in the same way, and developed for the
same time in order to avoid false results. After developing, the reaction was
stopped by immersing the slides in aqua.dest. Counterstaining was performed
with haemalaun for 2 minutes followed by washing the slides under running tap
water, which resulted in blue nuclei. Sections were then mounted with glycerol
mounting medium and allowed to dry.
4.11. In-situ apoptosis assay
The terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end
labeling (TUNEL) method labels fragmented DNA which is a characteristic of the
apoptotic cells. The TUNEL method identifies apoptotic cells in situ by using
terminal deoxynucleotidyl transferase (TdT) to transfer biotin-dUTP to these
strand breaks of cleaved DNA. The biotin-labeled cleavage sites are then
detected by reaction with HRP conjugated streptavidin and visualized by a
substrate. The following protocol was used for detecting TUNEL positive cells in
this study. Sections were treated and permeabilized in the same way as
described in immunohistochemistry method in this section. After
permeabilization, sections were placed in a humid chamber and 50µl of enzyme
solution was given to all sections, except to the negative control where enzyme
solution was omitted. In order to carefully spread the solution all through the
sections and to avoid drying, parafilm was used to cover them. This chamber
was incubated at 37oC for 1 hour, followed by washing. 50µl TUNEL AP
(converter AP, conjugated with alkaline phosphatase) was then given to each
section, covered with parafilm and incubated at 37oC for 30 minutes, followed by
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washing. The substrate used here was Fast red, which was freshly prepared by
dissolving one fast red tablet in 2ml 0.1M Tris-HCl, pH 8.2 and filtering through a
0.22µm filter. This substrate solution was given to all sections and allowed to
develop in dark, carefully monitoring the colour development under light
microscope. Reactions were then stopped by placing the sections in washing
buffer. Counterstaining with haemalaun and mounting was performed in the
same way as described in immunohistochemisty method in this section.
4.12. Microscopy
All stained sections were analysed by scanning each slide in Mirax scanner from
Carl Zeiss. The mirax viewer software was used to analyze and make snapshots
of the stained tissue sections.
4.13. Isolation of alveolar epithelial cells
Alveolar epithelial cells were isolated from 3 months old HPS1/2 double mutant
mice and their background control mice. 3 mice per group were taken for one
isolation and this was performed for 3 times. Panning antibody (CD16/44 and
CD45) coated plates were prepared one day prior to the isolation procedure by
addition of 15µl of each antibody in 10ml RPMI medium and stored at 4°C
overnight. These plates were transferred to 37°C incubator just before beginning
the isolation procedure. Mice were anesthetized and dissected in the same way
as mentioned under the description of animals in this section. Once the trachea
was revealed, a tubus was fixed into it. Lavaging was then down for 3 times.
Thymus was removed and the right atrium was carefully opened. The lung was
cleared from blood by flushing with 20ml 0.9% NaCl through the left ventricle.
1.5ml dispase was injected into the lung through the tubus. 0.4ml melted agarose
was then injected into the lung. The lung was then carefully taken out of the
thorax and incubated for 45 minutes in 1ml dispase at RT. 5ml of + medium was
taken into a cell culture dish under the laminar flow. The heart, trachea,
bronchus, etc were removed and the tissue was minced with the help of scissor
and pipetted thoroughly until a cell suspension was reached. Suspensions from
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all the three mice were pooled and filled to a final volume of 50ml. This
suspension was then filtered through different filter gazes (10µm, 20µm and
100µm) and sufficient +medium was used to avoid conglomeration. Filtered
suspensions were poured in 50ml falcon tubes and centrifuged at 200xg for 10
minutes at 14oC.
After centrifugation, the supernatant was carefully removed and the pellet was
resuspended in 1ml +medium. Suspensions were pooled and –medium was
added to a final volume of 30ml. These suspensions were plated on CD coated
dishes, which were prepared one day before by adding 50µl of CD45 and 30µl of
CD16/32 antibodies per 10ml –medium and stored at 37oC / 4% CO2. 5 plates
coated with these antibodies were used for isolation of primary cells from 3 mice.
After plating the suspensions, these plates were incubated for 45 minutes at
37oC / 4% CO2 for 45 minutes, followed by transferring the suspensions onto
non-coated dishes and incubating them at 37oC / 4% CO2 for 30 minutes.
Suspensions were then pooled and centrifuged at 300xg for 5 minutes at 4oC.
The supernatant was then removed and the pellet was resuspended in an
appropriate volume of +medium. Nile red staining was performed and the
epithelial cells were counted. Purity of the cells was checked by
immunoflourescence and the rest of the cells were frozen after a brief
centrifugation.
Culture medium +Medium -Medium
2% L-Glutamine 2% L-Glutamine 2% L-Glutamine
10% FCS 1% Pen/Strep 1% Pen/Strep
1% Pen/Strep 10mM HEPES 10mM HEPES
10mM HEPES DMEM DMEM
DMEM 4%(w/v) DNAse
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4.14. Densitometry analysis
The densitometry analysis was performed using the spot denso software from
Alpha Innotech. Integrated density Values of targeted proteins were first
normalized against those of actin values. The values of controls were then
assumed as 100% and the percent of increase or decrease of a target protein
was calculated.
4.15. Statistics
Unless indicated otherwise, all data in the figures and text are expressed as
means ± SEM of 3-8 mice. Statistical evaluation was performed by unpaired t-
test with subsequent Mann – Whitney test. Significance is indicated by *p<0.5,
**p<0.05, ***p<0.005.
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5. Results
5.1. General appearance and phenotype of HPS mice
All the three mono mutant mice (HPS1, HPS2, HPS6) and the two double mutant
mice (HPS1/2 and HPS1/6) mice were viable and showed a regular social
behaviour until the end of the observation period of 9 months. Body weights of
these mouse mutants were not significantly different from those of the respective
control mice between the ages of 3 and 9 months. Pale ear was the phenotype of
HPS1 mouse and the mouse imposed with a black coat colour. The coat colour
was pearl white for HPS2 and black for HPS6 mutants. The eye colour was black
for HPS1 and HPS2 mutants and deep red for HPS6 mutant, so the HPS1/2 and
HPS1/6 double mutants revealed a phenotype of pale ear/pearl and pale
ear/ruby eye, respectively. A major difference in breeding efficiencies was
observed. The breeding efficiency of single mutants, where only one protein
complex with either HPS1 (BLOC-3¯ ), HPS2 (AP-3¯ ) or HPS6 (BLOC-2¯ ) was
deficient, was uncompromised as compared with that of C57BL/6J control mice.
Similarly, there was no difference in breeding efficiencies of homozygous double
mutants involving the HPS1 and HPS6. In contrast, a significant drop in breeding
efficacy was illustrated by the HPS1/2 (BLOC-3¯ , AP3¯ ) homozygous mice.
5.2. Lung histology of HPS mice
To investigate the extent of lung disease in HPS monomutant (HPS 1,2,6) and
double mutant (HPS 1/2, 1/6) mice, H&E and trichrome stainings of lung sections
were performed. In the HPS 1/2 double mutant mice, but not in any of the other
mice investigated, sporadic development of lung fibrosis was evident already at
low magnification and at an age of 3 months (Fig.10A-a). Being patchy at the
beginning, the extent of lung fibrosis progressed over time and at an age of large
parts of the lungs were compensated (Fig.10A-b). At higher magnification,
extensive cellular infiltration and extracellular matrix deposition was evident. With
regard to the spatial distribution, the early fibrotic changes appeared to be more
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prominent in the subpleural areas of the lungs. At a higher magnification, lung
structure appeared to be roughly preserved in most areas, with
lymphoplasmacellular infiltration and increased collagen content of septae
(Fig.10B-k,l). However, in the most concerned regions dense fibrosis was
prominent and did not allow further differentiation with regard to the basic
alveolar structure. Especially in the younger HPS 1/2 mice still limited extent of
fibrosis, alveolar type II cells could be evaluated and showed a distinct
phenotype, with a dramatic increase in cell size, a “swollen” aspect and an
apparently increased content of lamellar bodies (Fig.10B-a,b).
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Figure 10: Histology of HPS mice A) Representative H&E stainings of complete right lungs of
HPS mono mutant, double mutant, and their background control mice at 3 and 9 months age. B)
Representative 20x magnification pictures of H&E and trichrome stained lungs of all the HPS
mutants & WT controls analyzed in this study at (a-j) 3 months and (k-x) at 9 months (n=5-10
mice per group).
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In the HPS 1 (Fig.10B-o,p) and 2 (Fig.10B-q,r) mono mutant, and even more in
the HPS 1/6 (Fig.10B-m,n) double mutant mice, air space enlargement was a
prominent finding. The HPS6 mice lungs (Fig.10B-i,j,s,t), however, showed
normal structure when compared with their background controls (Fig.10B-u,v).
5.3. Surfactant alterations in HPS mice
5.3.1. Altered processing and transport of the hydrophobic surfactant
proteins
In order to characterize surfactant metabolism in the HPS mouse models
mentioned, a stepwise surfactant analysis starting with the surfactant proteins
was performed, in particular, the hydrophobic surfactant proteins –B and –C in
bronchoalveolar lavage fluid (BALF) as well as in lung tissue.
5.3.1.1. Reduction in mature SP-B & mature SP-C in BALF occurs almost
exclusively in HPS1/2 mice: Equal volume of BAL fluids from all the HPS mice
were subject to SDS PAGE and western blot analysis of mature SP-B and
mature SP-C. While mature SP-B was undetectable already at the age of 3
months in HPS1/2 mice BAL fluid, it appeared to be reduced in HPS1/6 mice and
remained unaltered in all the HPS mono mutant mice analyzed until the age of 9
months (Fig.11A). Similarly, significantly reduced levels of mature SP-C were
observed in the HPS1/2 mice BAL fluid at the age of 3 and 9 months, but
appeared unchanged in the HPS1/6 double mutant and all the single mutants
analyzed until the age of 9 months (Fig.11B). As the mature hydrophobic
surfactant proteins were found to be severely reduced especially in HPS1/2 mice
BAL fluid, intracellular processing of these hydrophobic surfactant proteins in the
lung tissue of HPS1/2 mice and all other HPS mice were further assessed.
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A) SP-B
B) SP-C
Figure 11: Mature hydrophobic surfactant proteins in BALF of HPS mice: Western blot
analysis of A) mature SP-B and B) mature SP-C in BALF from all the double and mono mutant
HPS mice along with their respective WT controls at the age of 3 and 9 months. Equal volume
(20µl of BAL fluid per sample) was used for each analysis (n=5 mice per group).
5.3.1.2. Extensive intracellular surfactant protein accumulation in HPS1/2
double mutant mice : HPS1/2 and control mice lung homogenates were
subjected to SDS-PAGE followed by western blotting for pro and mature forms of
both SP-B and SP-C. This analysis revealed a prominent increase in the levels of
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almost all forms of SP-B and SP-C when compared to their background controls
(Fig. 12, 15). The 19kDa processing form of pro SP-B were already elevated in 3
month old HPS1/2 mice and at the age (Fig. 12) of 9 months. Similarly, a
significant increase in the mature SP-B levels was already observed in 3 month
old and it was much more severe in the 9 month old mice.
A)
B)
Figure 12: Alteration of surfactant proteins in HPS1/2 mice: A) Western blot analysis of lung
homogenates of 3 month (left panel) and 9 month (right panel) old HPS1/2 double mutant and
control mice (n=5 per group). Left panel shows 3 month old mice and right panel shows 9 month
old mice. All forms of tissue hydrophobic surfactant proteins were analysed (proSP-B, mature
SP-B, proSP-C, mature SP-C). B) Western blot analysis of isolated alveolar epithelial cells and
lung homogenates from 3 month old HPS1/2 mice and WT control mice (n=3 mice per group).
Please note that blots have been developed to show adequate staining for HPS1/2 mice samples,
longer development forwarded staining for mature SP-C also in controls.
3months 3months
HPS-1/2 Controls
9months 9months
HPS-1/2 Controls
40
25
20
40
25
20
10 10
20 20
10 10
40 40
42 kDa
25 kDa
19 kDa
pro SP-B
8.6 kDa
21 kDa
pro SP-C
matureSP-C
4.2 kDa
β-actin
matureSP-B
Co
n
tr
o
ls

mature – SP-C
mature – SP-B
ß - actin
10
40
Isolated
AECII
Lung
homogenate
M
kDa
10
H
PS
1/
2
Co
n
tr
o
ls

H
PS
1/
2
Results 51
The pro SP-C and mature SP-C levels enormously increased both in 3 and 9
month old HPS1/2 mice (Fig.12A). This clearly illustrates a severe accumulation
of hydrophobic surfactant proteins in the lung homogenates of these mice. To
check if this increase particularly refers to an accumulation of surfactant proteins
in AECII, alveolar epithelial cells were isolated from 3 month old HPS1/2 mice
alongside with WT controls and analyzed these isolated cells for mature SP-B
and mature SP-C, by western blotting. A clear accumulation of mature SP-B and
mature SP-C was observed in AECII of HPS1/2 mice when compared with those
of controls (Fig.12B). With such severe accumulation of surfactant proteins in
AECII and drastic decrease in the levels of mature surfactant proteins in BAL, it
was concluded that there is a severe defect in distal lysosomal transport and
surfactant secretion by AECII in HPS1/2 mice.
5.3.1.3. Surfactant protein alterations in HPS1/6 double mutant mice :
Western blot analysis of HPS1/6 double mutant mice lung tissue revealed a
significant increase in the 19kDa form of pro SP-B (Fig.13A), however, the tissue
levels of mature SP-B, pro and mature SP-C were not significantly different from
the background controls even at the age of 9 months (Fig.13A).
Figure 13: Alteration of surfactant proteins in HPS1/6 mice: Western blot analysis of lung
homogenates of 3 month (left panel) and 9 month (right panel) old HPS1/6 double mutant and
control mice (n=5 per group). Left panel shows 3M old mice and right panel shows 9M old mice.
All forms of tissue hydrophobic surfactant proteins were analyzed (pro SP-B, mature SP-B, pro
SP-C, mature SP-C).
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5.3.1.4. Surfactant protein alterations in HPS mono mutant mice : HPS1,
HPS2 and HPS6 along with control lung homogenates were subjected to
SDS-PAGE followed by western blotting for pro and mature forms of SP-B
and pro and mature forms of SP-C. An increase in the 19kDa pro SP-B
processing intermediate was observed in lung tissues from 9 month old
HPS1 mice. There was no significant increase in the levels of mature SP-B
and pro SP-C. However, mature SP-C levels were slightly increased in the
9 month old HPS1 tissue (Fig.14A). In HPS2 mono mutant mice, a slight
increase in the 19kDa pro SP-B processing intermediate was observed,
but mature SP-B remained unchanged. In the same way, there was an
increase in the pro SP-C levels as compared to controls, and no major
changes were observed with regard to mature SP-C (Fig.14B). In HPS6
mono mutant mice, elevated levels of 19kDa form of pro SP-B in lung
tissues of 9 month old HPS6 mice tissue was observed, but the levels of
mature SP-B, pro SP-C and mature SP-C remained unchanged when
compared with WT controls (14C). With these observations, it was
concluded that the surfactant protein processing and transport were
severely affected in HPS1/2 double mutant mice, partly in HPS1/6 mice
and almost unaffected in the mono mutant mice as compared with WT
control mice.
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B) HPS2
C) HPS6
Fig 14: Alteration of surfactant proteins in HPS mono mutant mice: Western blot analysis of
hydrophobic surfactant proteins for A) HPS1 B) HPS2 and C) HPS6 mono mutant and WT control
mice. Left panel shows 3 month old and right panel shows 9 month old mice. Western blots were
performed for pro SP-B, mature SP-B, pro SP-C and mature SP-C in lung tissue of these mice
(n=5 mice per group).
5.3.1.5. Comparative analysis of surfactant protein alterations in HPS mice:
For better comparison between the different HPS strains, intensity of each pro
and mature SP-B/C band of each HPS and control mouse lung homogenate was
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assessed by densitometric analysis and referred to the b-actin band of the same
SDS-PAGE. Expression of each protein form in HPS was then related to the
band intensity of the respective control run on the same gel (Fig.15). Such
comparative analysis forwarded almost unchanged or even reduced 42kDa pro
SP-B levels in all HPS mice, a roughly threefold increase in the 25kDa (Fig.15B)
and the 19kDa (Fig.15C) processing intermediates of pro SP-B, reaching
significance for all HPS mice in case of 19kDa pro SP-B. With regard to mature
SP-B (Fig.15D), a striking and fivefold increase was encountered in the lung
homogenates of HPS1/2 mice, whereas mature SP-B did not change
dramatically in the lungs of the other HPS mice.
A) 42kDa proSP-B B) 25kDa proSP-B
C) 19kDa proSP-B D) mature SP-B
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Fig 15: Alteration of surfactant proteins in HPS mice: Densitometric analysis of blot intensity
of all forms of SP-B (A – D) and SP-C (E &F). Normalized IDV of blot intensities of respective
proteins of HPS mice as percentage over control mice are given. (p value summary: *p<0.05,
**p<0.01, ***p<0.001, n=5 mice per group).
With regard to SP-C, there were no significant changes of 21kDa pro SP-C and
mature SP-C in the HPS 1/2/6 single and the HPS 1/6 double mutant mice, with
the exception of a roughly threefold increase of mature SP-C in HPS 1 mice.
However, in the HPS 1/2 mice, a dramatic increase of both, pro SP-C and mature
SP-C was evident already at the age of 3months (Fig. 15 E & F). Whereas pro
SP-C levels were already fivefold increased at that time point and did not
increase anymore in the older HPS 1/2 mice, the mature SP-C levels were
increased 15fold. This was paralleled by the severe accumulation of pro and
mature forms of SP-C (Fig. 15 E & F respectively) in the same lungs. With the
exception of accumulation of the 19kDa processing intermediate form of the pro
SP-B in HPS1/6 double mutant mice lung homogenates (Fig.15C) and reduction
in the mature SP-B in the same lungs (Fig.15D), the surfactant proteins
otherwise remained unaltered in the lung homogenates of all the single mutant
mice and the HPS1/6 double mutant mice.
5.3.2. Phospholipidosis in HPS mice
Since phospholipids represent bulk compounds of surfactant, total phospholipid
content of lung homogenates was analyzed in all 3 and 9 month old HPS mono
E) proSP-C F) mature SP-C
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mutant and HPS double mutant mice along with their background controls.
Phospholipid content was increased in all HPS mice, however, with a varying
extent. The weakest increase of phospholipids was encountered in HPS 1/6
(~1.5 fold), the strongest in HPS 1/2 mice (~ 3fold; Fig.16). Of note, there was a
statistical significant difference between the HPS 1/2 and all other HPS mice with
regard to the phospholipid content. In addition, it seems noteworthy to mention
that in contrast to the changes in mature SP-B and SP-C, the phospholipids
content of HPS 1/2 lung homogenates did not further increase beyond the age of
three months.
Figure 16: Alteration of surfactant lipids in HPS mice lung homogenates: Total
phospholipids were extracted from lung tissue of all the 3 and 9 month old HPS mono and double
mutant mice and their background controls (n=5 mice per group) according to Bligh & Dyer
method, and phosphate assay was performed as described in methods. The resulting
phospholipid concentrations were normalized against their respective protein concentrations and
values are expressed as µg phospholipids per mg protein of respective sample. (p value
summary: *p<0.05, **p<0.01, ***p<0.001).
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5.3.3. Lipidomic profiling of HPS lung tissues
Lipidomic analysis of lung tissues from all 9 month old HPS and control mice was
performed. As evident from Table 2, extensive alterations of the phospholipids
were found especially in the HPS1/2 mice. HPS1/2 mice showed marked
differences in almost all depicted phospholipids, when compared with controls.
While significant increase in PC was observed, a reduction in the rest of
phospholipid classes was observed in HPS1/2 lung tissue. As evident from
Table.4, significant differences in different phospholipids were observed in all
other HPS mice at varying levels.
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5.3.3.1. Accumulation of PC and surfactant specific DPPC in HPS1/2 mice :
Analysis of different classes of phospholipids by GC-MS based lipidomics
approach in lung tissues of all the HPS mutants revealed a significant increase in
the saturated phosphatidylcholine fraction of HPS1/2 mice, followed by HPS1/6
mice (Table.4, Fig.17A). The increase in PC is mainly due to an increase in PC-
32:0 (Fig.17B), which is dipalmitoylated fraction of PC and represents the most
abundant single compound of the surfactant system.
A)
B)
Fig 17: Phosphatidylcholine in HPS mice: A lipidomic study was performed as described in the
methods section for both 3 and 9 month old HPS single and double mutant mice along with their
background controls. Column graphs are depicted here representing A) subclass distribution of
PC fraction B) relative content of DPPC within the PC fraction. The values are expressed as %
mol of the respective lipid class, related to total PC. (*p<0.05, **p<0.01, ***p<0.001,n.s.=not
significant; n=5 mice).
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5.3.3.2. Glucosylceramides in HPS mice: Lipidomics study revealed that the
glucosylceramides are significantly and specifically increased in 9 month old
HPS1/2 mice tissue when compared with controls as well as with the other HPS
mice (Table 3). These glucosyl ceramides are synthesized by intracellular
glycosylation of ceramides, a reaction which is carried out by the enzyme
glucosylceramide synthase. Since glucosyl ceramides were increased in HPS1/2
mice, a semi-quantitative RT-PCR was performed, to check if such increase in
glycosylceramides could be ascribed to an altered regulation of the
glucosylceramide synthase. However, any meaningful difference in the
glucosylceramide synthetase mRNA expression in HPS1/2 versus control mice
was not observed (Fig.18).
Fig 18: Glucosylceramidesynthase in HPS1/2 mice: Semi-quantitative RT-PCR was performed
for glucosyl ceramide synthase and β-actin as described in the methods. Molecular weight is
expressed in base pairs. (n=5-7 mice).
SPM DihSPM Cer GluCer
Bl_6 Controls 90.0 ± 0.52 4.0 ± 0.53 4.8 ± 0.15 0.8 ± 0.08
HPS1/2 86.6 ± 1.6 5.9 ± 1.0 4.8 ± 0.31 1.5 ± 0.27 **
HPS1 88.4 ± 0.36 5.0 ± 0.8 4.5 ± 0.42 0.6 ± 0.06
HPS2 89.3 ± 0.4 4.2 ± 0.15 4.8 ± 0.13 0.6 ± 0.03
HPS6 90.5 ± 0.23 4.3 ± 0.51 4.4 ± 0.06 0.6 ± 0.05
HPS1/6 Controls 90.7 ± 0.73 3.4 ± 0.73 4.8 ± 0.11 0.5 ± 0.06
HPS1/6 91.0 ± 0.46 3.0 ± 0.11 4.7 ± 0.28 0.4 ± 0.11
200
200
400
HPS1/2 Controls
Glucosylceramide
synthase
β-actin
M(bp)
Table 5: Increased glucosylceramides in HPS1/2 mice lung tissues: Each
lipid here represents % mol of total lipids given in this table. Values are given as
± standard error means. Cer- Ceramides; Glucer- Glucosylceramides.
Significant difference compared to the controls: (**p<0.01; where significance is
not mentioned, values are considered not to be significant. n=5 mice).
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5.4. AECII undergo early and extensive apoptosis in HPS1/2
mice
Accumulation of surfactant in the AECII and its impaired secretion in HPS1/2
mice lungs might lead to cellular stress in the cell, ultimately leading to apoptosis,
by various pathways. To identify apoptotic AECII in the lung tissue of these mice,
TUNEL staining, alongside with immunohistochemistry for the AECII specific
marker pro SP-C was performed on serial sections of all HPS and control mice.
As depicted in Fig. 19A-c,e, numerous TUNEL positive AECII were evident in the
lung tissue of HPS1/2 mice already at an age of 3 months, indicating that AECII
apoptosis is an early event in the course of the HPS 1/2 induced lung fibrosis.
TUNEL positivity was not observed in any of the controls (Fig.19A-a), the other
HPS single (Fig.19B) or double mutant mice (Fig19C) analyzed here.
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B)
C)
Figure 19: AECII apoptosis in HPS1/2 mice: 3µm serial sections were obtained from paraffin
embedded lungs of A) HPS1/2 & WT controls B) HPS1, HPS2, HPS6 C) HPS1/6 and control
mice. Serial sections were either stained for TUNEL assay (upper panel) or immunostained for
pro SP-C (lower panel). Identical regions were identified and photographed using Mirax viewer
software. Arrows indicate same cells stained positive for TUNEL and pro SP-C. Magnification:
20x; (n=3 mice per group).
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In a complementary approach, apoptosis was assessed by performing
immunohistochemistry for cleaved caspase 3, alongside with pro SP-C on serial
sections of HPS1/2 and control mice lungs. It was found that the pro SP-C
positive cells also stained positive for cleaved caspase-3 in HPS1/2 tissue
sections (Fig. 20, right panel), while no signal for cleaved caspase-3 was
detected in control mice tissue sections (Fig. 20, left panel). Thus, cleaved
caspase 3 immunohistochemistry fully confirmed the TUNEL data and again
suggests that AECII undergo apoptosis in a caspase-3 dependent manner in
HPS 1/2, but not in the other HPS or control mice.
Figure 20: Caspase-3 dependent apoptosis of type II pneumocytes of HPS1/2 mice: 3µm
serial sections were performed from paraffin embedded lungs of 9 month old HPS1/2 and control
mice. Sections were immunostained either for cleaved caspase-3 (upper panel) or with pro SP-C
(lower panel). (n=3 mice per group). Arrows indicate same cell stained for both cleaved caspase-
3 and pro SP-C. Magnification: 40x.
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5.5. Early lysosomal stress underlies AECII apoptosis in HPS
1/2 mice
As already described, lamellar bodies of AECII are lysosome related organelles
and are the subcellular storage and secretion forms of surfactant in AECII.
Observations till this point indicated that intracellular accumulation of surfactant
was especially prominent in HPS 1/2 mice, which also spontaneously developed
lung fibrosis, and may be related to the increased apoptosis of AECII in HPS 1/2.
To further study the pathways that may interconnect surfactant accumulation and
AECII apoptosis in HPS1/2 mice, it was hypothesized that such surfactant
accumulation may primarily cause lysosomal stress in these mice. Therefore, a
well known lysosomal aspartyl protease, cathepsin D, was analyzed by western
blotting of lung homogenates of HPS1/2 and control mice. Increased levels of pro
cathepsin D (44kDa), glycosylated form (54kDa) and subsequent cleavage
products were observed in lung tissues from both 3 month and 9 month old
HPS1/2 mice when compared with their controls (Fig.21A). In parallel, cathepsin
D levels were analyzed also in AECII, isolated from both, HPS1/2 and control
mice lungs at the age of 3 months. Interestingly enough, increased levels of pro
cathepsin D, its glycosylated form and its cleavage products were found in these
AECII of HPS1/2 mice when compared to those of controls (Fig.21B). To check if
this was based on an altered cathepsin D gene expression level, semi-
quantitative RT-PCR for cathepsin D was performed, but did not forward
significant changes when compared with controls (Fig.21C).
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A)
B)
C)
Figure 21: AECII specific lysosomal stress in HPS1/2 mice: Western blot analysis of
cathepsin D in A) lung homogenates at the age of 3 and 9 months (n=5 mice per group) and in B)
isolated AECII at the age of 3months of HPS 1/2 and WT control mice (n=3 mice per group). C) A
semi-quantitative RT-PCR analysis for the expression of cathepsin D and β-actin from HPS1/2
and control mice lung RNA (n=6mice per group).
5.5.1. Lysosomal stress is specific in HPS1/2 mice
Since HPS in general is known to effect lysosome related organelles, it was
further checked if lysosomal stress could be detected in all other HPS mutants.
For this purpose, cathepsin D levels were analyzed by western blot in lung
homogenates of all HPS mice mentioned in this study. Interestingly, it was
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observed that up-regulation of cathepsin D forms was exclusively found in
HPS1/2 mice (Fig. 22B), but in none of the other HPS mouse mutants (Fig. 22
A,B & C). This indicates the existence of a lysosomal stress response exclusively
in HPS1/2 mice.
A)
B)
C)
Figure 22: Lysosomal stress is specifically found in HPS1/2 mice: Western blot analysis for
cathepsin D in reducing lung homogenate samples of 9month old (A) HPS1, HPS2 and WT
controls (B) HPS6, HPS1/2 and WT controls (C) HPS1/6 and WT controls. Gels were run, blotted
and developed under same conditions for all the samples. (n=5 mice per group).
5.5.2. Cathepsin D mediated apoptosis in HPS1/2 mice: To study if increased
cathepsin D would colocalize with cleaved caspase 3 and pro SP-C in HPS1/2
lungs, serial sections were stained for all three proteins. Identical regions from
HPS1/2 lungs on three different sections showed positivity for all the three
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proteins (Fig.23a, b, c), proving that AECII are indeed showing colocalization of
these markers with enhanced cathepsin D staining.
Fig 23: Cathepsin D mediated apoptosis of AECII in HPS1/2 mice: Immunohistochemistry on
3µm serial paraffin sections of HPS1/2 (upper panel) and WT (lower panel) mice for cleaved
caspase 3 (a,d), pro SP-C (b,e) and cathepsin D (c,f) in HPS1/2 double mutant mice. Arrows
indicate positive staining of AECII for all three proteins. Arrow heads (in f) indicate cathepsin D
staining of macrophages in control mouse lung section. Magnification:20x. (n=3mice per
group).
5.6. Induction of ER stress in HPS1/2 mice
Apart from the lysosomal stress response, the possible existence of an
endoplasmic reticulum (ER) stress response was also assessed in the HPS
mice. For this purpose, the late ER stress marker CHOP (GADD 153), which is
involved in ER-stress induced apoptosis was studied. Western blot analysis of
CHOP in HPS1/2 and control mice lung homogenates revealed that CHOP is
indeed upregulated in HPS1/2 mice. Interestingly, only the 9 month old mice, but
not the 3 month old HPS1/2 mice, showed an increase in CHOP protein level
when compared to age matched controls (Fig. 24A). To check if CHOP is
Pro SP-C Cathepsin DCleaved caspase 3
a b c
d e f
H
PS
1/
2
B
l_
6
Co
n
tr
o
l
Results 68
expressed in AECII, immunohistochemistry of CHOP and pro SP-C was
performed on serial sections of 9 month old HPS1/2 and control mice.
Interestingly, these stainings illustrated that pro SP-C positive cells stained
positive for CHOP in HPS1/2 mice sections (24B, right panel), while control mice
sections showed no positivity for CHOP staining (Fig. 24B). Thus, it was
concluded that AECII from HPS1/2 mice undergo ER stress during the later
stage of the disease.
A)
B)
Fig 24: AECII specific induction of ER stress in HPSIP: A) Western Blot analysis for CHOP
protein in lung homogenates of HPS1/2 mice and age matched WT controls (n=5 mice per group)
B) 3µm serial sections were performed from paraffin embedded lungs of 9 month old HPS1/2 and
WT control mice. Arrows indicate AECII stained positive for both CHOP and proSP-C.
Magnification: 20x (n=3mice per group).
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5.7. Alveolar type II cell apoptosis due to lysosomal and ER
stress is a prominent finding in human HPSIP
Further, lysosomal and ER stress compounds in human HPSIP was
characterized. Lack of frozen lung material from transplanted human HPS
patients restricted the current work to the available paraffin sections, which were
received from two HPS patients from the NIH. Hence, imunohistochemistry was
performed on serial lung sections of these patients to assess lysosomal or ER
stress in AECII. Interestingly, AECII from HPSIP patients not only showed much
more pronounced immunohistochemical staining for pro SP-C as compared to
donor lungs, (Fig.25A-b) but also showed a positive staining for both cleaved
caspase 3 (Fig.25A-a) and cathepsin D (Fig.25A-c) in the AECII, confirming the
data observed in the HPS1/2 mice. Noteworthy information here is that, in both
WT control mice (Fig.23f) and healthy donors (Fig.25A-f), cathepsin D is found to
localize more in the macrophages and not in the AECII, as indicated by arrow
heads. ER stress was then studied on these sections again by
immunohistochemistry on serial sections with CHOP and pro SP-C antibodies. It
was observed that AECII of HPS1 patients (Fi5.25B-b) showed positive staining
for CHOP (Fig.25B-a) whereas AECII from donor lungs did not stain for CHOP at
all (Fig.25B-b).
Results 70
Fig 25: AECII apoptosis due to lysosomal stress and ER stress in human HPSIP:
Immunohistochemistry on 3µm serial paraffin sections of one human HPS1 patient and healthy
donors for A) cleaved caspase 3 (a,d), pro SP-C (b,e) and cathepsin D (c,f). Magnification: 20x.
Arrow heads (in f) indicate cathepsin D staining of macrophages in healthy donor lung sections.
B) CHOP (a,c) and pro SP-C (b,d). Magnification:40x. Arrows indicate positive staining of AECII
for the proteins analyzed. (n=2 for both HPS1 patient sections and healthy donor sections).
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6. Discussion
The initial focus of this study on HPS mice was to correlate their genotype and
phenotype. For this purpose, the extent of lung disease was examined and
surfactant processing and transport was characterized in HPS1/2, and HPS1/6
double mutant mice, their corresponding single mutant mice (HPS1, HPS2 and
HPS6) and WT controls. HPS1/2 double mutant mice showed initial fibrotic
changes at the age of 3 months and fully blown fibrosis at the age of 9 months.
Another important observation is the appearance of emphysema as well as
pulmonary fibrosis in this model. Air space enlargement, but not lung fibrosis was
present to varying degrees in HPS1, 2, 6 and 1/6 mice. Surfactant analysis of
both phospholipids and mature surfactant proteins revealed most severe
accumulation in alveolar epithelial type II cells (AECII) in HPS1/2 mice both at 3
and 9 months of age and was found to be parallelled by extensive AECII
apoptosis due to cellular stress mechanisms, which are discussed in the
following sections. These key findings in mice could be fully reproduced in
human lung sections from patients with HPSIP. Hence, these studies indicate
that a) the magnitute of altered surfactant processing and transport correlates
with the development of lung fibrosis, b) severe disturbance of surfactant
processing and transport correlates with AECII aopptosis, c) age dependent
accumulation of surfactant and severity of apoptosis correlates with the
progression of fibrotic lung disease and d) distal lysosomal transport of surfactant
is impaired, but not fully abrogated in HPS1/2 mouse model. The following
aspects deserve extensive discussion:
6.1. Role of HPS gene products in surfactant processing and
transport
Studies from other groups revealing abnormal appearance of alveolar structures
[107, 108] and this study showing increased phospholipids in the lung tissues of
both HPS1 and HPS2 mono mutant mice imply that the actions of AP-3 and
BLOC-3 are possibly required in the distal compartments of AECII. Absence of
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either BLOC-3 or AP-3 seems to retard surfactant transport or processing. It is
not known if the gene product generated by the monomutant BLOC-3 or AP-3
gene in HPS1 or HPS2 respectively would result in a much more pronounced
phenotype and alterations of surfactant processing, if its function could not be
partially rescued by other proteins. In any case, absence or loss of function of
both the protein complexes as in HPS1/2 double mutant mouse model, seems to
result in an over additive effect, resulting in the extensive alterations of the
intracellular surfactant pool and the severe phenotype illustrated herein.
AP-3 (muted in HPS2) has been suggested to cargo proteins from trans-golgi
network (TGN) and early endosomes to late endosomes or lysosomes [109]. It is
known to be recruited to membranes by ADP-Ribosylation Factor-1 (ARF-1)
[110]. AP-3 binds to tyrosine sorting signals. It is essential for the normal
melanosomal delivery of tyrosinase [111, 112]. It is also required for efficient
localization of P-selectin to Weibel-Palade bodies, which are secretory granules
of endothelial cells and a loss of AP-3 function as in pearl and mocha mouse
mutants leads to a defective localization of P-selectin [113]. More than one AP-3
mediated lysosomal pathway exists. The first is the direct pathway from TGN to
early and late endosomes. The second pathway is an indirect route, where AP-3
facilitates membrane traffic from TGN to lysosomes via an intracellular route, that
bypasses early endosomes [114]. Depending on their sorting motifs, lysosomal
membrane proteins exploit AP-3 to use these two different pathways. For
example, the lysosomal delivery of endolyn, a lysosomal mucosialin, occurs
predominantly via the indirect pathway [114], while the lysosomal delivery of
CD63/LAMP3 occurs via the direct pathway [115]. When direct pathway was
inhibited by chloroquine (a lysomotropic weak base and neutralizes the pH of
endosomal compartments), the wild type CD63 (with GYEVM AP-3 binding motif)
was trapped in early endosomes, while its mutant (with GYEVI AP-3 binding
motif) was not at all found in early endosomes, but was trafficked via the indirect
pathway [115].
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The precise function of BLOC-3 (muted in HPS1 or HPS4) on the other hand, is
unknown. But, it is implicated to regulate a) the movement or distribution of late
endosomes and lysosomes and b) optimal attachment of late endocytic
organelles to microtubule dependent motors. Binding partners or target proteins
for BLOC-3 have not yet been identified, with the exception of one study, where
decreased perinuclear staining of LAMP1 in late endocytotic organelles was
observed in BLOC-3 defecient mouse skin fibroblasts [91]. In addition, mutations
of BLOC-3 resulted in accumulation of stage-I melanosomes in mouse dorsal
black follicular melanocytes. In mouse tail epidermal melanocytes, a more
pronounced block in melanosome biogenesis leading to relatively decreased
melanosomes was observed [101]. Thus, BLOC-3 seems to be differentially
regulated in melanocytes.
But, how do defects in AP-3 and BLOC-3 affect lysosomal trafficking and lung
lamellar bodies in AECII? It is proposed that BLOC-3 regulates endosomal and
lysosomal movements, mediated by both microtubule and actin dependent
mechanisms and to maintain normal function of several important proteins
involved in the secretory pathway [92]. Hence, it could be speculated that one or
more motility factors, which mediate attachment to or movement along
microtubules are either decreased in amount or missing due to mistargeting in
HPS. Another explanation could be that, factors which mediate events like
vesicle docking, targeting or fusion at plasma membrane are missing.
As discussed earlier, there is an over additive affect in HPS1/2 mouse model.
One immediate explanation for this effect could be that there is a direct
interaction between BLOC-3 and AP-3. However, previous studies undertaking
immunoprecipitation experiments in fibroblasts and B-lymphoblastoid cells did
not show such interaction between the two protein complexes [72, 91]. Moreover,
intracellular localization of AP-3 complex was not altered in fibroblasts from
patients with HPS1 mutation. In addition, abnormal trafficking of lysosomal
membrane proteins, like lysosome associated membrane protein-1 (LAMP-1),
was observed in HPS2 mutant cells, but not in HPS1 fibroblasts [116]. Inspite of
Discussion 74
all this valuable information, a role of HPS1 protein in the AP-3 dependent
pathway or vice-versa cannot be completely ruled out because all cited previous
reports were performed in non-secretory or non lung secretory cells. In addition,
cell type specific differences in lysosomal enzyme secretion of BLOC-3 mutants
were reported [92]. Supporting this theory, studies dealing with a patient with
HPS2 mutation (mutation on β3A subunit of AP-3), demonstrated that lytic
granules, which are lysosome related organelles of cytotoxic T lymphocytes,
showed impaired microtubule dependent movement [117], a feature that has
been ascribed to BLOC-3.
In case of a missing direct interaction between BLOC-3 and AP-3 in AECII, other
binding partner(s) for these protein complexes, which may play a major role in
surfactant secretion and the function of which may be more heavily affected, if
both BLOC-3 and AP-3 are absent. Hence, additional experiments focussing on
interactions between BLOC-3 and AP-3 and identification of binding partners
specifically in the surfactant secretory pathway might enhance the understanding
towards molecular pathways underlying the alteration of surfactant transport and
processing in HPS1/2 mice.
6.2. Altered surfactant processing or transport occurs in other
forms of ILDs, too
Surfactant alterations have been described in some other lysosomal storage
disorders and interstitial lung diseases apart from HPS. Chediak-Higashi
syndrome (CHS) is not only a lysosomal storage disease, but it also falls into the
category of albinism, where patients are reported to show bleeding disorders and
severe immune deficiency. The mouse mutant of CHS is the beige mouse, which
also shows giant lamellar body degeneration soon after birth, with an increased
severity at older ages. The older mice show signs of fibrosis, with an increased
accumulation of lamellar body lipids [104, 118]. Another model that is not directly
belonging to the group of HPS, but falls into the category of occulocutaneous
albinism, is the chocolate mouse mutant which is caused by a mutation of the
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Rab38 gene. Rab 38 encodes a small GTPase, which participates in regulating
vesicular trafficking and is found at high levels in lung [119]. A human counterpart
for the murine Rab38 mutation has not yet been reported. Nevertheless, in a
recent study, enlarged airspaces in the lungs of these mice have been reported.
As compared to wild type mice, the number and size of AECII, as well as the
hydrophobic surfactant constituents were increased in the lungs [119]. However,
there are no data yet with regard to the existence of lysosomal stress and
epithelial apoptosis in these mice.
Another important lipid storage disorder is the Niemann-Pick disease that has
also been associated with surfactant alterations. It was primarily identified as a
neurovisceral lipid storage disorder, but lung involvement has been later
identified in some types of the disease. The disease is primarily caused by
sphingomyelinase deficiency (Niemann-Pick type C2; NPC2) [120]. Most
interestingly, severe interstitial pneumonia has been observed in NPC2 neonatal
patients [121]. Recent study in NPC2 patients showed the association of NPC
type 2 with alveolar proteinosis. Foamy macrophages and enlarged AECII were
observed, with accumulation of lipid rich material in the alveolar lumina and
cytoplasmic inclusions of AECII [122]. In addition, progressive pulmonary
infiltration has been observed in the concerned patients. In full accordance, ASM
(acid sphingomyelinase) knock out mice lungs show cellular infiltration and
significantly elevated levels of phosphatidylcholine, phosphatidylserine and
phosphatidylethanolamine alongside with increased sphingomyelinase in both
lung tissue and BAL fluid [123]. Histologic evidence of fibrosis development was
not reported in ASM knockout mice, at any age [124].
In some few familial forms of idiopathic interstitial pneumonia, mostly with a usual
interstitial pneumonia (UIP) or nonspecific interstitial pneumonia (NSIP) pattern,
mutations in the SFTPC (surfactant protein-C) gene have been described [125,
126]. In these families, pro SP-C and active SP-C were either barely detectable,
or COOH based missence or short deletion mutations resulted in the production
of a misfolded protein [126]. In the latter patients, aberrant subcellular localization
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of SP-C precursor protein was seen, with dense fibrosis and distorted AECII
architecture [127,128]. In line with this study, in vitro trafficking experiments
showed that constructs with mutations in BRICHOS domain of SP-C form large
toxic intracellular aggregates, termed aggresomes, leading to cellular stress
[129]. In addition, SP-C -/- mice, developed on a 129/sv background strain,
showed a severe lung phenotype. Although lungs looked normal at birth,
progressive emphysema, accumulation of lung tissue phospholipids and severe
pulmonary fibrosis were observed at 2 months after birth [130]. Taken together,
both the entire absence of SP-C or the production and accumulation of an
abnormal, misfolded pro SP-C can result in the development of a diffuse
parenchymal lung disease.
Finally, mutations in the ATP binding cassette subfamily A/3 (ABCA3) gene in
pediatric patients have been reported to cause fatal surfactant deficiency as well
as interstitial lung disease, depending on the phenotype. ABCA3 is specifically
concentrated to the limiting membrane of lamellar bodies and is proposed to play
a major role in the excretion of lipid fraction of pulmonary surfactant. Frameshift,
nonsence mutations or mutations in the highly conserved regions of this gene
lead to disturbed lipid trafficking in newborns [131 - 133]. Electron microscopy
pictures revealed abnormally small and dense lamellar bodies in AECII of such
patients. Recently, UIP pattern of pulmonary fibrosis has also been reported in
an adolescent patient with ABCA3 mutations [134].
Taken together, disturbances of the delicate intracellular homeostasis of
surfactant compounds seem to prone the AECII to chronic injury and appear to
be responsible for the observed phenotypes (airway enlargement and fibrosis).
6.3. Lysosomal and ER stress reflect epithelial stress in HPS1/2
mice
6.3.1. Altered surfactant processing and trafficking as underlying reason
for AECII injury: One of the key observations in this study is the extensive
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intracellular accumulation of mature surfactant proteins and surfactant specific
DPPC in the AECII of HPS1/2 mice. Although being still indirect in nature, the
data set provided in this study strongly suggests a causative relationship
between defective surfactant transport and processing, induction of AECII
apoptosis and development of lung fibrosis in HPS1/2 mice. The following two
cellular stress patterns need to be discussed as underlying reason for chronic
AECII injury:
6.3.2. Lysosomal stress: Lysosomes are membrane bound organelles which
contain hydrolytic enzymes for digesting macromolecules. Several proteases,
nucleases and phospholipases, cathepsins (B, D, H, L, S, F, K, C, W, X, V, and
O) are present in lysosomes, which optimally work at an acidic pH around 5. The
limiting membrane of the lysosome contains a set of highly glycosylated,
lysosomal-associated membrane proteins (LAMPs) such as LAMP-1, LAMP-2
and CD63/LAMP-3, the functions of which are still unclear. Morphologically
heterogenous, the lysosomes often resemble other organelles of the endocytic
and secretory pathways. These organelles share many traits of the lysosomes
like the presence of mature acid-dependent hydrolases and LAMPs. They are
however termed as “Lysosome Related Organelles” (LROs) [135], as they lack
the lysosomal marker mannose 6-phosphate receptors (MPRs). Examples of
LROs, as mentioned earlier are: melanosomes, lytic granules, major
histocompatibility complex (MHC) II compartments, platelet dense granules,
basophil granules and lamellar bodies of the lung. The shared traits of these
specialized organelles may be biogenetically related to lysosomes, a relationship
that has been further illuminated by the multiorganellar, lysosomal storage,
genetic disorders such as the Hermansky-Pudlak and Chediak-Higashi
syndromes.
As described previously, these genetic diseases can result in the
accumulation/storage of undigested substances within the LROs, resulting in a
severe “lysosomal stress”, with serious pathologic consequences. Programmed
cell death might be one serious consequence of such severe stress. There is no
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known marker for lysosomal stress till date. Of course, lysosomal enzymes and
proteases offer as markers. Elegant studies from other groups showed increased
activities of the lysosomal enzymes β-Glucoronidase and β-Galactosidase in the
lungs and kidneys of HPS1/2 mice [136]. However, these studies did not relate
the increased enzymatic activities to the AECII, nor did they associate these
enzymes with apoptosis of AECII or any other cell type in this mouse model. In
order to study the role of these lysosomal enzymes in driving the AECII into what
is here described as “lysosomal stress” and subsequent apoptosis, the lysosomal
aspartyl protease cathepsin D was opted. Cathepsin D has numerous functions
within the lysosomal compartment, of which the best known is the proteolysis of
endocytosed and autophagocytosed proteins at low pH. Much more interesting in
the context of this investigation is, however, the observation that cathepsin D
also plays a critical role in the induction of apoptosis, as previously shown in
many cell types [137]. In addition, it has been shown under conditions of
oxidative stress, that caspase-8 mediated apoptosis is dependent on cathepsins,
especially cathepsins D and L [138]. Under conditions of bleomycin induced lung
fibrosis, cathepsin D activates caspase–3 in bleomycin-induced apoptosis of
alveolar epithelial cells, via the angiotensin (ANG II) pathway [139, 140]. The
induction of apoptosis is based on two different major pathways, one being the
extrinsic pathway, which involves the connection of appropriate ligand with the
surface receptor (Fas), and which results in activation of caspase-8, -10 and -3.
The intrinsic pathway is activated in case of mitochondrial dysfunction, which
leads to release of caspase activators, that inturn yields activation of caspase-9,
and, in consequence, caspase-3 [141]. In neuroblastoma cells subjected to
oxidative stress, cathepsin D, and not cathepsin B, was shown to be responsible
for the activation of the intrinsic pathway of apoptosis. Under these conditions,
the action of cathepsin D was essential for the translocation of Bax from the
cytosol to mitochondria and hence,the activation of the intrinsic pathway of
apoptosis [142]. A combination of both the pathways results when caspase-8
induces proteolysis of Bid to truncated Bid (tBid). In addition, lysosomal
destabilization in neutrophils triggered cleavage of pro-apoptotic Bcl2 protein Bid,
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followed by a decrease in anti-apoptotic protein, Mcl-1 [143]. tBid is transported
through mitochondrion where it initiates oligomerization of Bax and induces
intrinsic pathway of apoptosis (Fig.26). Which of these pathways are activated in
HPSIP has yet to be identified and it is currently a matter of research.
6.3.3. ER stress: The Endoplasmic Reticulum (ER) has a central role in the
production of almost all lipids and proteins. All proteins designated for secretion
and all proteins designated for the ER itself, the golgi apparatus, the lysosomes,
the endosomes are first imported into the ER from the cytosol, or directly
synthesized into the ER lumen by altered ribosomes. Proteins fold and
oligomerize, disulphide bonds are formed and N-linked oligosaccharides are
added within the ER lumen [144]. Proteins that do not fold or oligomerize
correctly despite the action of chaperons are translocated back into the cytosol,
where they are deglycosylated, ubiquitinilated and degraded in proteasomes. If
misfolded proteins accumulate excessively in the ER, they trigger an unfolded
protein response (UPR), which under normal conditions activates appropriate
genes in the nucleus to help the ER to cope. Similarly, extensive protein overload
of the ER (eg. in the form of viral infection) results in an ER overload response
[145].
Conditions interfering with the function of ER are collectively called ER stress.
ER stress primarily aims to prevent further accumulation of proteins. However, if
the stress cannot be resolved and the cellular responses fail to eliminate the
unfolded proteins, the cell undergoes apoptosis [146, 147]. At present, the exact
signalling mechanism underlying ER stress-induced apoptosis is poorly
understood. Nevertheless, different pathways, a transcription factor, a caspase-
dependent, and a JNK-dependent pathway have been identified. CHOP/GADD
153 has been shown to be activated via the cleavage of ATF6, ATF4, along with
alternative XBP1 splicing, which are inturn induced by phosphorylation of PERK
[148,149].
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CHOP is a 168 aminoacid (in rodents) protein, with a molecular weight of 20kDa.
It is expressed ubiquitously at low levels. It is also known as DNA damage-
inducible transcript–3, and growth arrest and DNA damage inducible gene
(GADD). The CHOP protein is a heterodimer with C/EBPs. It comprises of an N-
terminal transcriptional activation domain and a C-terminal basic–leucine zipper
(bZIP) domain, consisting of a basic amino-acid-rich DNA-binding region followed
by a leucine zipper dimerization motif [150, 151]. Furthermore, the CHOP protein
contains two adjacent serine residues (79 and 82) which can serve as substrates
for the p38 MAP kinase family. Deletion mutant analysis of CHOP revealed that
bZIP domain is important for CHOP-induced apoptosis [149]. It is expressed
ubiquitously at low levels and is strongly expressed by various factors like
glucose deprivation and amino acid starvation [151]. Agents like tunicamycin,
thapsigargin and dithiothreitol strongly induce CHOP expression. As discussed
before, CHOP is regulated on a transcriptional level by distinct ER stress
transducers. Overexpression of CHOP has been reported to cause cell cycle
arrest, leading to apoptosis. Reduced apoptosis in response to ER stress has
been reported in CHOP knock out mice. In addition, lymphocytes from spleen of
CHOP knockout mice have been shown to be resistant to LPS-induced apoptosis
[152]. These data prove that CHOP plays a prominent role in ER stress induced
apoptosis.
Of late, ER stress has been implicated in the pathogenesis of many
neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease
[153]. A relation between surfactant and ER stress was first reported in a study
which showed that a mutation in the BRICHOS domain of the SP-C precursor
protein leading to the accumulation of its mutant protein in the ER, elicited ER
stress followed by apoptosis in epithelial cell lines [154]. A recent study from our
group focussing on sporadic cases of idiopathic pulmonary fibrosis has
demonstrated the importance of ER stress in driving the AECII apoptosis, a
feature that was not detected in COPD patients, but only in the IPF subjects
[155]. In these patients, no mutations of the two hydrophobic surfactant proteins,
SP-B and SP-C were observed, but defective intracellular processing of SP-B,
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reuslting in accumulation of proSP-B has been found to underlie the development
of ER stress in these patiens (unpublished).
6.3.4. Other possible mechanisms leading to lysosomal or ER stress: With
respect to mouse models, a silver mutation, that is characterized as a recessive
mouse mutant with progressive coat colour dilution has been reported to have a
loss of ER export and endocytic signals, with altered melanosome morphology
[156]. Apart from this, gangliosides, which are formed from precursor molecules
ceramides, also act as apoptotic signals in ER stress response. These
gangliosides mainly reside in the ER and regulate membrane dynamics and
structure of this organelle; hence, changes in ganglioside compositions can have
deleterious consequences like the induction of ER stress [157]. In addition,
accumulation of GM1 ganglioside in a mouse model of GM1-gangliosidosis, a
lysosome storage disorder, was shown to activate the UPR, causing neuronal
death [158]. Other important members of the ceramide super family are glucosyl
and galactosyl ceramides, the accumulation of which causes Gaucher disease
and Krabbe disease, respectively, which are LSDs [159, 160]. Gaucher’s disease
is caused because of excess accumulation of glucosylceramide, particularly via
the deficiency of gluco-cerebrosidase or glucosylceramidesynthase. GlcCer are
synthesized on the cytosolic surface of Golgi and may flip to the luminal leaflet of
Golgi membrane where it can enter the luminal aspect of transport vesicles.
Interestingly, GlcCer is a substrate of for the ABC-transporters MDR-1 P-
glycoprotein and MRP1 [160]. Besides the well known lysosomal sequesteration
of GlcCer, an alternative pathway is supposed to exist to dispose it. In non-
macrophage cells, GlcCer is believed to be transferred from lysosomes to other
cell compartments by an unknown mechanism, where it is processed or even be
accumulated to varying degrees. In line with these studies, elevated levels of
GlcCer resulted in an increase in ER density, suggesting that GlcCer are also
transported retrogradely to the ER [160]. In short, accumulation of GlcCer is
possible either in lysosomes or in ER, thereby resulting in cellular stress
mechanisms. However, lysosomal storage disorders have not yet been directly
implicated to cause ER stress via ER overload in non-neuronal cells. But,
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accumulation of GlcCer in HPS1/2 lung tissue in this study adds another proof to
a possible cellular stress. Cell specific and/or sub-cellular organelle specific
studies are however required in order to identify the organelle specific GlcCer
accumulation in HPS model.
6.3.5. Integrative concept of induction of AECII apoptosis in HPS1/2 lungs:
This study discloses a prominent role of AECII in HPSIP in both mice and man. A
simplified version of AECII of HPSIP in comparision with a healthy AECII is
shown in the cartoon below (Fig.28). The AECII of HPS1/2 mouse is
exceptionally big, with giant lamellar bodies. Important surfactant components
like SP-B, SP-C and phospholipids are shown to be accumulated in such a cell.
An overload of these surfactant components and their abnormal secretion leads
to a severe cellular stress.
As indicated in the picture below, cathepsin D, CHOP and glucosylceramides
were significantly increased with AECII of HPS1/2 mice, confirming the lysosomal
and ER stress mechanisms in these mice, which were corroborated by human
HPSIP tissue sections. Thus, this increase in different cellular stress markers is
thereby eliciting the activation of caspases, finally leading to apoptosis of such an
AECII in these mice. However, whether these cellular stress mechanisms
orchestrate with each other or act independently to activate effector caspases
and thereby apoptosis, has yet to be deciphered in HPSIP.
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Figure 26: Induction of AECII apoptosis in HPSIP lungs: Cartoon depicting a healthy AECII
where surfactant processing and secretion is normal and a HPSIP AECII, where giant lamellar
bodies, altered surfactant transport and abnormal secretion of surfactant is shown. An increase in
cathepsin D, Glccer and CHOP are shown, all leading to apoptosis of the cell. Please note the
size difference between the healthy AECII and the HPSIP AECII.
6.4. The role of AECII injury in the development of lung fibrosis
in general and HPSIP in particular
6.4.1. AEC II injury underlies HPSIP: Several studies focussed on the
cellular biology of HPSIP. Abnormalities have been reported in two major cell
types, the AECII and alveolar macrophages. While macrophages are heavily
loaded with ceroid material, AECII cells were shown to be enlarged, with giant
lamellar bodies in HPSIP patients. In a HPS2 mouse model, activation of
macrophages and baseline elevations in inflammatory cytokines was reported.
The authors of that study showed that the alveolar macrophage activation seen
in both HPS1 and HPS2 mouse mutants is not genotype specific [161].
Healthy AECII HPSIP AECII
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Supporting this view, decreased lysosomal enzyme secretion from macrophages
was observed in HPS1 mice [80]. Likewise, although macrophage activation was
observed in HPS1 and HPS2 single mutant mouse models, development of
pulmonary fibrosis was illustrated only after targeting AECII of these mice with
bleomycin challenge [162]. The data from this work drive home the point that
injury to and apoptosis of AECII in HPS1/2 double mutant mice represents the
key event in HPSIP and it is forwarded by two cellular stress mechanisms,
lysosomal and ER stress. Supporting this notion are data from human IPF as well
as the herein described human HPSIP patients, where alveolar epithelial cell
injury and cell death are a consistent finding. Precise mechanism(s) by which
apoptosis of AECII may result in lung fibrosis is yet not settled, but may include
the following mechanisms: downregulation of prostaglandin E2 (PGE2), increase
in pro-fibrotic growth factors like transforming growth factor-β (TGF-β), epithelial
to mesenchymal transition (EMT) or cell-cell contact.
6.4.2. Endogenous regenerative responses to the AECII injury in HPSIP:
Extensive loss of AECII as suggested in ALI / ARDS, causes a life threatening
condition due to the denudation of basement membrane and the flooding of the
alveolar space. However, alveolar edema is not a prominent feature of IPF, or
HPSIP. It appears therefore reasonable, to anticipate a marked activation of
progenitor or local stem cells in HPSIP lungs, in order to limit the patho-
physiological consequences of AECII apoptosis. Hyperproliferation of AECII in
IPF has been indicated, as a strategy to overcome the loss of epithelium. Wnt
signalling is one such pathway that has been implicated in epithelial cell
hyperplasia and proliferation in IPF lungs [163, 164]. Notch signalling is another
pathway, which is involved in cell fate decisions [165]. Significant reduction in
Notch protein and mRNA level were observed in the lung tissue of bleomycin
induced lung fibrosis in mice [166]. Added to this, altered Notch signalling has
been observed in the lungs of IPF patients (unpublished). In rat model of
bleomycin induced lung fibrosis, transplantation of AECII from healthy rats
proved to be effective, as the extent of lung fibrosis significantly reduced [167].
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Apart from these considerations, the injured AECII lung may try to limit the
consequences of distorted surfactant transport and processing in HPSIP, through
activation of survival genes. For example, cells transfected with SP-C∆exon4
(which causes misfolded SP-C, leading to chronic ER stress), showed an
increase in NF-kB activity [168]. Inflammation shown in HPS monomutant mice
(HPS2 or example) [161], sublethal injury of AECII possibly causes inflammatory
changes like activation of NF-kB and related survival genes, which help the
AECII to survive. Because of an uncontrolled injury due to severe accumulation
of surfactant and subsequent cellular stress where the function of survival genes
is not sufficient, the AECII in HPS1/2 mice undergo apoptosis. Hence, it can be
concluded that in murine HPSIP (HPS1/2), the AECII response pattern largely
dictates the nature of the evolving lung disease.
6.4.3. Additional factors that possibly contribute to AECII apoptosis in
HPSIP: An incease of the alveolar surface tension has been suggested to largely
contribute to the loss of lung compliance and the impairment of gas exchange in
patients with ALI / ARDS. According to more recent studies, extensive stretch of
AECII, as it may occur because of the collapse of alveolar units due to increased
alveolar surface tension or because of inappropriately high tidal volumes applied
during mechanical ventilation, significantly adds to AECII apoptosis [169]. The
underlying molecular mechanisms of such “over” stretch induced apoptosis of
AECII still remain to be elucidated. However, it appears reasonable that increase
in alveolar surface tension, as already shown for IPF patients, could contribute to
the pathomechanism of HPSIP. Interestingly, such increase has very recently
been disclosed in the HPS1/2 mice by our group (unpublished).
6.5. Murine HPSIP: A model for IPF and other “idiopathic”
forms of lung fibrosis?
The present investigation is the first study to identify HPS1/2 double mutant
mouse as a murine model for HPS associated interstitial pneumonia (HPSIP).
Observations from this murine model are supported by those of human HPS1
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patients. Apart from the development of pulmonary fibrosis in the mouse model,
a first hand evidence was provided here, that AECII apoptosis, resulting from
lysosomal stress and ER stress is involved in the development of HPSIP in mice
and man.
The human HPSIP shares its prognosis with IPF. HRCT findings from HPSIP
patients appear to be the same as those of IPF patients. Moreover, HPSIP
demonstrates usual interstitial pneumonia (UIP) pattern, histologically. Inspite of
its genetic origin, the murine HPSIP model shares common features with IPF,
and thus portrays as a new animal model of IPF. IPF is characterized by
progressive deposition of fibrotic tissue in the pulmonary interstitium with minimal
associated inflammation, a feature that is also seen in the HPS1/2 mice. Similar
to IPF, alveolar epithelial cell injury, AECII hyperplasia and progressive loss of
normal lung architecture can be attributed to murine HPSIP as well. On a
biochemical level, altered surfactant processing and secretion has been
observed in both IPF and murine HPSIP. In both cases, AECII injury appears to
represent the primary trigger. Apart from this, the response of AECII indicating
the induction of ER stress as well as activation of lysosomal enzymes [170] is
similar in mice and man with HPSIP and IPF.
Upto now, bleomycin induced lung fibrosis in mice has been the standard model
for most researchers in order to study the mechanisms underlying lung fibrosis in
general and IPF in particular. This model however has its own drawbacks, like
excessive inflammation prior to the onset of lung fibrosis and reversal of fibrosis
after several weeks of bleomycin challenge. For this reason, the HPS1/2 double
mutant mice may serve as an extremely valuable and important model not only to
study further disease relevant patho mechanisms, but also to design, develop
and scrutinize therapeutic strategies for patients with HPSIP as well as IPF.
6.6. Therapeutic strategies
As mentioned above, successful therapeutic strategies have not been developed
for HPSIP, with lung transplantation remaining as the only curative, which is itself
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not an uncomplicated approach for pulmonary fibrosis till date. Based on the
observations from HPS mouse models in the present study, the following
therapeutic options can be proposed. As indicated, HPS mono mutant mice
present milder phenotype when compared with HPS1/2 mice. Hence, correction
of phenotype of HPS1/2 mice by over expressing AP-3 in AECII specific manner
might compensate some of the functions within the secretory pathway.
In addition, since apoptosis of AECII represents such a predominant finding in
human and murine HPSIP, it may be worth to evaluate the therapeutic efficacies
of PAN caspase inhibitors to modify the AECII stress response and thus, lung
fibrosis. Apart from this, transplantation of stem cells has been proposed as a
strategy for repair of lung fibrosis, but controversial results with this kind of
approach restrict the potential use of these cells. An attempt to transplant AECII
from healthy rats into bleomycin challenged rats forwarded positive results with
regard to the extent of lung fibrosis [167]. Accordingly, syngenic transplantation
of AECII from healthy WT littermates into HPS1/2 mice, following an
experimental period of about 3 months, might possibly reverse the fibrosis in this
mouse model and successfully result in the replacement of the AECII by the
donor AECII. A potential therapeutic outlook for HPSIP patients could be the
transplantation of ex vivo differentiated iPS (induced Pluripotent Stemcells) into
AECII and subsequent transplantation.
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7. Summary
Hermansky-Pudlak syndrome (HPS) comprises of a group of rare hereditary
disorders primarily affecting transport within lysosome related organelles. Up to
now, 16 (mice) and 8 (human) genes, respectively, have been found to cause
this disease. Amongst other clinical symptoms, patients with HPS may develop
lung fibrosis (HPS associated Interstitial Pneumonia; HPSIP). As a consequence
of such organ involvement, quality of life is then greatly reduced and prognosis is
poor. The underlying molecular reasons for the development of HPSIP had yet
not been settled. However, on an ultrastructural level, patients with HPSIP
impose with an abnormal enlargement and increased number of lamellar bodies,
a lysosome related organelle of alveolar type II cells (AECII) that represents the
intracellular storage and secretion form of pulmonary surfactant.
Drawn against this background, the genotype-phenotype correlation was
analyzed in mice with different single and combined HPS mutations. This work
primarily focussed on the extent of pulmonary fibrosis and performed an in depth
surfactant analysis in the lungs of HPS1, HPS2, HPS6, HPS1/6, HPS1/2 and
respective wild type mice. In addition, altered signalling pathways and cellular
consequences were studied.
Histological studies, undertaken after 3 and 9 months of age, revealed that only
HPS1/2 mice, but none of the other HPS mice, would develop lung fibrosis, being
quite extensive by 9 months of age. In these mice, but in none of the other mice,
AECII appeared swollen and seemed to contain more and larger lamellar bodies.
On the other hand, especially the HPS1/6 mice revealed spontaneous
development of airspace enlargement. Defective intracellular surfactant
trafficking and secretion was a prominent finding in HPS 1/2 mice and caused a
highly significant intracellular accumulation of the mature hydrophobic surfactant
proteins SP-B and SP-C as well as phospholipids. Among the phospholipids,
especially the dipalmitoylated phosphatidylcholine (DPPC), the most abundant
surfactant compound, was significantly elevated in lung tissues of HPS 1/2 mice.
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Isolated AECII from these mice revealed similar results. In contrast, although
these above mentioned surfactant compounds appeared slightly increased in the
mono mutant and the HPS 1/6 mice, there was a significant difference between
HPS1/2 on the one, and the other mice on the other hand with regard to the
extent of disturbed intracellular transport and accumulation of surfactant
compounds.
As a possible consequence of such defective transport and secretion of
surfactant, AECII apoptosis was observed extensively in 3 and 9 month old
HPS1/2 mice by in-situ apoptosis assay and by immunohistochemistry of cleaved
caspase 3. Hypothesizing that apoptosis of AECII in HPS1/2 mice would develop
due to severe cellular stress, lysosomal and ER stress markers in these mice
were investigated. The lysosomal protease, cathepsin D, was highly elevated in
lung homogenates and isolated AECII of HPS1/2 mice, but, again, in none of the
other mutant mice. Such increase in cathepsin D was already visible at the age
of 3months. These results indicate an early onset lysosomal stress specifically in
HPS1/2 mice. Apart from this, HPS 1/2 mice also exhibited signs of severe ER
stress at a later age (9 months). In detail, CHOP, a proapoptotic factor
specifically induced by unresolved ER-stress, was found to be highly and
exclusively elevated HPS1/2 mice. In addition, lipidomic profiling of 9 month old
lung tissues from all HPS mice revealed increased levels of glucosylceramides
only in HPS1/2 mice, which also hints towards a serious cellular stress in these
mice.
Data from the HPS1/2 mouse model was aptly supported by those obtained from
HSPIP patients. As compared to lung transplant donor lungs, paraffin sections of
lungs from two HPSIP patients (HPS1 mutation) showed a highly increased
immunostaining for cathepsin D in AECII, alongside with induction of caspase-3
and CHOP immunostaining in this cell-type, thereby confirming the cellular stress
mechanisms as observed in HPS1/2 mice.
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Taken together, this is the the first time to decipher HPS1/2 mice as a valuable
animal model of human HPSIP. With regard to the clinical similarities and
common pathomechanistic principles between HPSIP and patients with
Idiopathic Pulmonary Fibrosis (IPF), HPS 1/2 mice also offer as the currently best
available model of IPF. This study showed that defective intracellular surfactant
trafficking in AECII of these mice leads to the development of lysosomal and ER
stress, finally resulting in AECII apoptosis, and – at the end - development of
lung fibrosis. Analysis of markers of lysosomal and ER-stress in human HPSIP
samples fully corroborated such pathomechanistic concept and lends further
credit to the general concept that apoptosis of the AECII represents a key step in
the development of lung fibrosis in non-inflammatory triggered forms of Interstitial
Lung Diseases. On the basis of these results, further elucidation of the molecular
mode of action and the binding partners of the concerned HPS gene products
(adaptor protein 3 and BLOC 3) appears reasonable and therapeutic strategies
aiming to either restore the defective transport mechanism or to block the cellular
stress response or AECII apoptosis are warranted.
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8. Zusammenfassung
Das Hermansky-Pudlak syndrom (HPS) umfasst eine Reihe seltener und
vererbbarer Erkrankungen, die primär alle zu einer Beeinträchtigung lysosomaler
Transportprozesse führen und klinisch ein vergleichbares Spektrum an
Beschwerden und Symptomen auslösen. Bis dato sind 16 (Maus) bzw. 8
(Mensch) verschiedene Gene bekannt, die im Falle einer Mutation die
Erkrankung auslösen können. Neben vielfältigen anderen
krankheitsdefinierenden Symptomen entwickeln viele betroffene Patienten eine
Lungenfibrose (HPS associated Interstitial Pneumonia; HPSIP). In diesem Fall
entwickelt sich eine deutliche Einschränkung der Lebensqualität und die
Prognose der betroffenen Patienten ist schlecht. Die der Entwicklung der HPSIP
zugrunde liegenden Pathomechanismen waren bis dato nicht bekannt, allerdings
wurde in früheren post-mortem Analysen ein auffälliges Erscheinungsbild der
alveolären Typ II Zellen (AECII) beschrieben, mit einer vermehrten Anzahl und
einer Vergrößerung der Lamellarkörperchen, dem lysosomalen Organell der
AECII, in dem pulmonaler Surfactant intrazellulär gespeichert wird.
Vor diesem Hintergrund war es das Ziel der vorliegenden Arbeit, eine Korrelation
des Genotyps mit dem Phänotyp bei verschiedenen mono- oder doppelt
mutanten HPS Mäusen (HPS 1, 2, 6, 1/2, 1/6) im Vergleich zum genetischen
Hintergrund durchzuführen. Im Fokus stand hierbei zunächst die Frage ob auch
bei murinen HPS Formen eine HPSIP auftritt und welche assoziierten
Veränderungen des Surfactantsystems hierbei beobachtet werden können.
Weiterhin wurden verschiedene zelluläre Stresspfade, wie lysosomaler Stress
oder Endoplasmatisches Retikulum (ER)-Stress, untersucht und mit den anderen
Befunden korreliert.
Die im Alter von 3 und 9 Monaten durchgeführten histologische Untersuchung
ergaben, dass ausschließlich die HPS 1/2 Mäuse eine Lungenfibrose
entwickelten, die mit 3 Monaten noch sehr diskret, mit 9 Monaten aber voll
ausgeprägt war. In diesen HPS 1/2 Mäusen, nicht aber in den anderen HPS
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Mäusen und Wildtyp Tieren, konnte auch ein den Patienten mit HPSIP
entsprechendes Erscheinungsbild der AECII beobachtet werden, mit einer
deutlichen Schwellung und einer Zunahme des Gehalts an Lamellarkörperchen.
Die im Anschluß durchgeführte Analyse des pulmonalen Surfactantsystems
ergab sowohl im Lungengewebe als auch in isolierten AECII der HPS 1/2 Mäuse
eine hochsignifikante Störung des intrazellulären Transports von Surfactant-
komponenten, die zu einer intrazellulären Akkumulation der maturen
hydrophoben Surfactant Proteine SP-B und SP-C sowie der Phospholipide
führte. Bzgl. der Phospholipide konnte vor allem eine hochsignifikante
Akkumulation des dipalmitoylierten Phosphatidylcholins (DPPC) in den Lungen
der HPS 1/2 Mäuse beobachtet werden. Obwohl auch in den anderen HPS
Mäusen eine moderate Störung der intrazellulären Surfactanthomöostase
beobachtet werden konnte, war der Unterschied dieser Veränderungen zwischen
den HPS 1/2 und den anderen HPS und den Wildtyp Tieren doch erheblich und
ebenfalls hochsignifikant.
As mögliche Folge dieses hochgradig gestörten intrazellulären Surfactant-
transports konnte ausschließlich in den HPS 1/2 Mäusen, und zwar bereits im
Alter von 3 Monaten, eine Apoptose der AECII mittels der TUNEL Methode oder
der Immunohistochemie (IHC) für gespaltene Kaspase 3 beobachtet werden. In
den anderen HPS oder Wildtyp Tieren war dies in keinem Fall zu beobachten.
Als zugrunde liegende zelluläre Stressreaktionen konnte zunächst eine Induktion
des Kathepsin D in den AECII der HPS 1/2, nicht aber in den anderen HPS
Mäusen, mittels Western Blot und ICH nachgewiesen werden. Dieser lysosomale
Stressmarker war bereits im Alter von 3 Monaten erhöht. Noch nicht in diesem
Alter, aber dann mit 9 Monaten ebenfalls prominent nachweisbar, war CHOP, ein
proapoptotisch wirksamer Faktor, der infolge eines anhaltenden und nicht
korrigierbaren ER-Stresses entsteht und zwingend mit der Entwicklung der
Apoptose einhergeht Auch dieses Faktor wurde exklusiv in den AECII von HPS
1/2 Mäusen beobachtet. Schließlich fiel im Rahmen von Untersuchungen des
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Lipidoms auch noch eine Erhöhung des relativen Anteils von Glukosylceramiden
auf, ebenfalls ein Marker für eine schwerwiegende Stressantwort der Zelle.
Die in den HPS 1/2 Mäusen gewonnenen Daten konnten im Lungengewebe von
zwei Patienten mit HPSIP vollständig reproduziert werden: auch hier fand sich im
Vergleich zum Lungengewebe von Organdonoren eine deutliche Induktion von
Kathepsin D und CHOP in den AECII, die zudem auch größtenteils Zeichen der
stattfindenden Apoptose aufwiesen.
Zusammengefasst konnte mit den HPS 1/2 Mäuse werden ein murines Korrelat
der am Patienten zu beobachtenden HPSIP beschreiben. Aufgrund der
Ähnlichkeiten hinsichtlich des klinischen Beschwerdebildes und der Prognose
dieser Patienten mit Patienten mit einer Idiopathischen Pulmonalen Fibrose
(IPF), stellen HPS 1/2 Mäuse unserer Meinung nach außerdem das derzeit beste
Modell der IPF dar. In diesen HPS 1/2 Mäusen bewirkt der gestörte intrazelluläre
Transport und Sekretion von Surfactantkomponenten einen frühen lysosomalen
Stress, gefolgt von einer späteren ER-Stress, die beide die Apoptose der AECII
und – über noch zu definierende Schritte – die Lungenfibrose auslösen. Die
Analyse von Markern eines lysosomalen und eines ER-Stresses in Patienten mit
HPSIP bestätigen in vollem Umfang dieses pathomechanistische Konzept und
stärken die Annahme, dass die unkontrollierte Apoptose der AECII ein
Schlüsselvorgang bei der Entwicklung nicht-inflammatorisch getriggerter Formen
der Lungenfibrose darstellt. Unsere Untersuchungen befürworten die weitere
Aufdeckung der molekularen Wirkungsweise und intrazellulärer Bindungspartner
der HPS 1/2 Genprodukte (Adaptor Protein 3, BLOC3) in den AECII.
Darüberhinaus erscheint die therapeutische Korrektur des gestörten Surfactant-
Transports wie auch die mögliche Blockade der lysosomalen- oder ER-Stress
Antwort in den AECII als hoffnungsvoller therapeutischer Ansatz der Behandlung
der HPSIP.
References 94
9. References
1. Scarpeli EM. The surfactant system of the lung. Int. Anesthesiol Clin.,
1977,15 (4) 19-60.
2. von Neergard K. Retraktionskraft der Lunge, abhängig von der
Oberflächenspannung in den Alveolen . Z Gesamte Exp Med, 1929, 66: 373-
394.
3. Pattle RE. Properties, function and origin of the alveolar lining layer. Nature
1995, 175: 1125-1126.
4. Clements JA. Surface tension of lung extracts. Proc Soc Exp Biol Med, 1957,
95: 170-172.
5. Gruenwald P. Surface tension as a factor in the resistance of neonatal lungs
to aeration. Am J Obstet Gynecol, 1947, 53: 996-1007.
6. Walter F. Boron, Emile L. Boulpaep. Medical Physiology. A cellular and
molecular approach. Saunders imprint of Elsevier science, ISBN 0-7216-
3256-4.
7. King R. Isolation and chemical composition of pulmonary surfactant. In:
Robertson B., van Golde L., Batenburg J. eds. Pulmonary Surfactant.
Amsterdam: Elsevier Science, 1984, 1-15.
8. Haagsman HP, van Golde LM. Synthesis and assembly of lung surfactant.
Annu Rev Physiol, 1991, 53: 441-464.
9. Hawgood S, Clements JA. Pulmonary surfactant and its apoproteins. J Clin
Invest, 1990, 86: 1-6.
10. Van Golde LM, Batenburg JJ, Robertson B. The pulmonary surfactant
system: biochemical aspects and functional significance. Physiol Rev, 1988,
68: 374-455.
11. Hawgood S. Surfactant: composition, structure, and metabolism. In: Crystal
RG, West JB eds. The lung, chapt. 3.1.10. New York: Raven Press, Ltd.,
1991: 247-261.
12. Shelley SA, Paciga JE, Balis JU. Lung surfactant phospholipids in different
animal species. Lipids, 1984, 19: 857-862.
13. Post M, Batenburg JJ, Schuurmans EA, Laros CD, van Golde LM. Lamellar
bodies isolated from adult human lung tissue. Exp Lung Res, 1982, 3: 17-28.
References 95
14. Magoon MW, Wright JR, Baritussio A, Williams M C, Goerke J, Benson BJ,
Hamilton RL, Clements JA. Subfractionation of lung surfactant. Implications
for metabolism and surface activity. Biochim Biophys Acta, 1983, 750: 18-31.
15. Günther A, Schmidt R, Feustel A, Meier U, Pucker C, Ermert M, Seeger W.
Surfactant subtype conversion is related to loss of surfactant apoprotein B
and surface activity in large surfactant aggregates. Experimental and clinical
studies. Am J Respir Crit Care Med, 1999, 159: 244-251.
16. Wright JR, Benson BJ, Williams MC, Goerke J, Clements JA. Protein
composition of rabbit alveolar surfactant subfractions. Biochim Biophys Acta
1984, 791: 320-332.
17. L.M.G.Van Golde. Synthesis of surfactant lipids in the adult lung. Annual
Review of Physiology, 1985, Vol.47:765-774.
18. Stephen E. McGowan and John S. Torday. The pulmonary lipofibroblast
(lipid interstitial cell) and its contributions to alveolar development. Annu. Rev.
Physiol., 1997. 59:43–62.
19. J.S. Torday and V.K.Rehan. The evolutionary continuum from lung
development to homeostasis and repair. Am J Physiol Lung Cell Mol Physiol,
2007, 292: L608–L611.
20. Machiko Ikegami. Surfactant catabolism. Respirology, 2006, Volume 11,
S24–S27.
21. Shelley SA, Balis JU, Paciga JE, Espinoza CG, Richman AV. Biochemical
composition of adult human lung surfactant. Lung, 1982, 160: 195-206.
22.Hamm H, Fabel H, Bartsch W. The surfactant system of the adult lung:
physiology and clinical perspectives. Clin Investig, 1992, 70: 637-657.
23. Harwood JL. Lung surfactant. Biochem Soc Trans, 1987, 15l: 80S-89S
(Suppl.).
24.Veldhuizen R, Nag K, Orgeig S, Possmayer F. The role of lipids in pulmonary
surfactant. Biochim Biophys Acta, 1998, 1408: 90-108.
25.Schlame M, Casals C, Rustow B, Rabe H, Kunze D. Molecular species of
phosphatidylcholine and phosphatidylglycerol in rat lung surfactant and
different pools of pneumocytes type II. Biochem J, 1988, 253: 209-215.
26.Kahn MC, Anderson GJ, Anyan WR, Hall SB. Phosphatidylcholine molecular
species of calf lung surfactant. Am J Physiol, 1995, 269: L567-L573.
References 96
27. Adachi H, Hayashi H, Sato H, Dempo K, Akino T. Characterization of
phospholipids accumulated in pulmonary-surfactant compartments of rats
intratracheally exposed to silica. Biochem J, 1989, 262: 781-786.
28. Hayashi H, Adachi H, Kataoka K, Sato H, Akino T. Molecular species profiles
of acidic phospholipids in lung fractions of adult and perinatal rabbits. Biochim
Biophys Acta, 1990, 1042: 126-131.
29. Fleming BD, Raynor CM, Keough KMW. Some characteristics of monolayers
of 1-palmitoyl-2-oleyl-phosphatidylglycerol with and without diplamitoyl-
phosphatidylcholine during dynamic compression and expansion. Biochim
Biophys Acta, 1983, 732: 243-250.
30. Meban C. Effect of lipids and other substances on the adsorption of
dipalmitoyl phosphatidylcholine. Pediatr Res, 1981, 15: 1029-1031.
31. Fleming BD, Keough KM. Surface respreading after collapse of monolayers
containing major lipids of pulmonary surfactant. Chem Phys Lipids, 1988, 49:
81-86.
32. Wright, J.R. Immunomodulatory functions of surfactant. Physiol. Rev. 1997,
77:931–962.
33. Korfhagen TR, Bruno MD, Ross GF, Huelsman KM, Ikegami M, Jobe AH,
Wert SE, Stripp BR, Morris RE, Glasser SW, Bachurski CJ, Iwamoto HS,
Whitsett JA. Altered surfactant function and structure in SP-A gene targeted
mice. Proc Natl Acad Sci U S A, 1996, 93: 9594-9599.
34. Wert, S.E., et al. Increased metalloproteinase activity, oxidant production,
and emphysema in surfactant protein D gene-inactivated mice. Proc. Natl.
Acad. Sci. USA, 2000, 97:5972–5977.
35. Carlos Botas, Francis Poulain, Jennifer Akiyama, Cindy Brown, Lennell Allen,
Jon Goerke, John Clements, Elaine Carlson, Anne Marie Gillespie, Charles
Epstein, and Samuel Hawgood. Altered surfactant homeostasis and alveolar
type II cell morphology in mice lacking surfactant protein D. Proc. Natl. Acad.
Sci. USA, 1998, V.95(20): 11869-11874.
36. Korfhagen TR, Sheftelyevich V, Burhans MS, Bruno MD, Ross GF, Wert SE,
Stahlman MT, Jobe AH, Ikegami M, Whitsett JA, Fisher JH. Surfactant
protein-D regulates surfactant phospholipids homeostasis in vivo. J Biol
Chem., 1998, 273(43):28438-43.
37. Palaniyar N, Clark H, Nadesalingam J, Shih MJ, Hawgood S, Reid KB.
Innate immune collectin surfactant protein D enhances the clearance of DNA
by macrophages and minimizes anti-DNA antibody generation. The Journal of
Immunology, 2005,174(11):7352-8.
References 97
38. William J. Janssen, Kathleen A. McPhillips, Matthew G. Dickinson, Derek J.
Linderman, Konosuke Morimoto, Yi Qun Xiao, Kelly M. Oldham, R. William
Vandivier, Peter M. Henson and Shyra J. Gardai. Surfactant Proteins A and D
Suppress Alveolar Macrophage Phagocytosis via Interaction with SIRP .
American Journal of Respiratory and Critical Care Medicine, 2008, Vol 178.
pp. 158-167.
39. Frank Brasch, Georg Johnen, Alexandra Winn-Brasch, Susan H. Guttentag,
Andreas Schmiedl, Nadine Kapp, Yasuhiro Suzuki, Klaus M. Müller, Joachim
Richter, Samuel Hawgood and Matthias Ochs. Surfactant Protein B in Type II
Pneumocytes and Intra-Alveolar Surfactant Forms of Human Lungs.
American Journal of Respiratory Cell and Molecular Biology, 2004, Vol. 30,
pp. 449-458.
40. Takayuki Ueno, Stig Linder, Cheng-Lun Na, Ward R. Rice, Jan Johansson,
and Timothy E. Weaver. Processing of Pulmonary Surfactant Protein B by
Napsin and Cathepsin H . Biol. Chem., 2004, Vol. 279, Issue 16, 16178-
16184, April 16.
41. Kristin D. Gerson, Cherie D. Foster, Peggy Zhang, Zhenguo Zhang, Michael
M. Rosenblatt, and Susan H. Guttentag. Pepsinogen C proteolytic processing
of surfactant protein B. J. Biol. Chem, 2008, 10.1074/jbc.M707516200.
42.Frank Brasch, Anja ten Brinke, Georg Johnen, Matthias Ochs, Nadine Kapp,
Klaus M. Müller, Michael F. Beers, Heinz Fehrenbach, Joachim Richter,
Joseph J. Batenburg, and Frank Bühling. Involvement of Cathepsin H in the
Processing of the Hydrophobic Surfactant-Associated Protein C in Type II
Pneumocytes. Am. J. Respir. Cell Mol. Biol., 2002, Volume 26, Number 6,
June 2002 659-670.
43. Soll, RF. Clinical trials of surfactant therapy in the newborn. In Surfactant
Therapy for Lung Disease Edited by Robertson B, Taeusch HW New York:
Marcel Dekker, 1995, pp. 407–442.
44. Beers MF, Hamvas A, Moxley MA, Gonzales LW, Guttentag SH, Solarin KO,
Longmore WJ, Nogee LM, and Ballard PL. Pulmonary surfactant metabolism
in infants lacking surfactant protein B. Am J Respir Cell Mol Biol., 2000, 22:
380–391.
45. Keisuke Tokieda, Jeffrey A. Whitsett, Jean C. Clark, Timothy E. Weaver,
Kazushige Ikeda, Keith B. McConnell, Alan H. Jobe, Machiko Ikegami, and
Harriet S. Iwamoto. Pulmonary dysfunction in neonatal SP-B-deficient mice.
Am J Physiol Lung Cell Mol Physiol., 1997, Vol. 273, Issue 4, L875-L882,
October.
46. D.K. Vorbroker, S.A. Profit, L.M. Nogee, J.A. Whitsett. Am. J. Physiol. Lung
Cell Mol. Physiol., 1995, 268; L647-L656.
References 98
47. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress
in adults. Lancet, 1967, 2: 319-323.
48. American Thoracic Society/European Respiratory Society International
Multidisciplinary Consensus Classification of the Idiopathic Interstitial
Pneumonias. This joint statement of the American Thoracic Society (ATS),
and the European Respiratory Society (ERS) was adopted by the ATS board
of directors, June 2001 and by the ERS Executive Committee, June 2001. Am
J Respir Crit Care Med., 2002, 165, 277-304.
49. Noble, P.W. & Homer, R.J. Back to the future: historical perspective on the
pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol.,
2005, 33, 113-20.
50. Katzenstein ALA, Myers JL: Idiopathic pulmonary fibrosis – Clinical relevance
of pathologic classification. American Journal of Respiratory and Critical Care
Medicine, 1998, 157:1301-1315.
51. Corrin, B., Dewar, A., Rodriguez-Roisin, R. & Turner-Warwick, M. Fine
structural changes in cryptogenic fibrosing alveolitis and asbestosis. J Pathol.,
1985,147, 107-19.
52.Myers, J.L. & Katzenstein, A.L. Epithelial necrosis and alveolar collapse in the
pathogenesis of usual interstitial pneumonia. Chest, 1988,94, 1309-11.
53. F. Hermansky and P.Pudlak. Albinism associated with hemorrhagic diathesis
and unsusual pigmented reticular cells in the bone marrow: Report of two
cases with histochemical studies. Blood, 1959, 14: 162-169.
54. Huizing and William A. Gahl, Mark Brantly, Nilo A. Avila, Vorasuk
Shotelersuk, Cynthia Lucero, Marjan. Pulmonary Function and High-
Resolution CT Findings in Patients With an Inherited Form of Pulmonary
Fibrosis, Hermansky-Pudlak Syndrome, Due to Mutations in HPS-1. Chest,
2000, 17; 129-136.
55. David J. Lederer, Steven M. Kawut, Joshua R. Sonett, Efsevia Vakiani,
Samuel L. Seward, James G. White, Jessie S. Wilt, Charles C. Marboe, MD,
William A. Gahl, and Selim M. Arcasoy. Successful Bilateral Lung
Transplantation for Pulmonary Fibrosis Associated With the Hermansky-
Pudlak Syndrome. , 2005, Volume 24, Issue 10,1697-1699.
56. Pulmonary fibrosis in Hermansky Pudlak Syndrome-A case report. Diane M.
Pierson, Diana Ionescu, Gefei Qing, Abdullah M. Yonan, Kent Parkinson,
Thomas C. Colby, Kevin Leslie. Respiration, 2006, 73:382–395.
57. Yukio Nakatani, Nobuo Nakamura Jinyu Sano, Yoshiaki Inayama Naomi
Kawano Shoji Yamanaka, Yohei Miyagi Yoji, Nagashima Chiho Ohbayashi,
Mutsue Mizushima Toshiaki Manabe, Makoto Kuroda Toyoharu Yokoi,
References 99
Osamu Matsubara. Interstitial pneumonia in Hermansky-Pudlak syndrome:
significance of florid foamy swelling/degeneration (giant lamellar body
degeneration) of type II pneumocytes. Virchows Arch., 2000, 437:304–313.
58.Anikster Y, Huizing M, White J, Shevchenko YO, Fitzpatrick DL, Touchman
JW, Compton JG, Bale SJ, Swank RT, Gahl WA, Toro JR: Mutation of a new
gene causes a unique form of Hermansky-Pudlak syndrome in a genetic
isolate of central Puerto Rico. Nat Genet., 2001; 28: 376–380.
59.Wildenberg SC, Oetting WS, Almodovar C, Krumwiede M, White JG, King
RA: A gene causing Hermansky-Pudlak syndrome in a Puerto Rican
population maps to chromosome 10q2. Am. J. Hum Genet., 1995, 57: 755–
765.
60. Witkop CJ, Nunez Babcock M, Rao GH, Gaudier F, Summers CG, Shanahan
F, Harmon KR, Townsend D, Sedano HO, King RA, et al: Albinism and
Hermansky-Pudlak syndrome in Puerto Rico. Bol. Asoc. Med. P. R., 1990; 82:
333–339.
61. Bachli EB, Brack T, Eppler E, Stallmach T, Trueb RM, Huizing M, Gahl WA:
Hermansky-Pudlak syndrome type 4 in a patient from Sri Lanka with
pulmonary fibrosis. Am. J. Med. Genet., 2004, 127A:201–207.
62.Schallreuter KU, Frenk E, Wolfe LS, Witkop CJ, Wood JM: Hermansky-
Pudlak syndrome in a Swiss population. Dermatology, 1993, 187: 248–256.
63. Izquierdo NJ, Royuela MA, Maumenee IH: Possible origins of the gene of
Hermansky- Pudlak in Puerto Rico. P R Health Sci J., 1993, 12: 147–148.
64.Poddar RK, Coley S, Pavord S: Hermansky-Pudlak syndrome in a pregnant
patient. Br J Anaesth., 2004, 93: 740–742.
65. Poletti V, Costabel U, Casoni GL, Bigliazzi C, Drent M, Olivieri D: Rare infi
ltrative lung diseases: a challenge for clinicians. Respiration, 2004, 71: 431–
443.
66. Li W, Rusiniak ME, Chintala S, Gautam R, Novak EK, Swank RT: Murine
Hermansky- Pudlak syndrome genes: regulators of lysosome- related
organelles. Bioessays., 2004, 26: 616–628.
67. Gwynn B, Martina JA, Bonifacino JS, Sviderskaya EV, Lamoreux ML,
Bennett DC, Moriyama K, Huizing M, Helip-Wooley A, Gahl WA, Webb LS,
Lambert AJ, Peters LL: Reduced pigmentation (rp), a mouse model of
Hermansky-Pudlak syndrome, encodes a novel component of the BLOC-1
complex. Blood, 2004, 104: 3181–3189.
References 100
68.Oh J, Bailin T, Fukai K, Feng GH, Ho L, Mao JI, Frenk E, Tamura N, Spritz
RA: Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder
of cytoplasmic organelles. Nat Genet., 1996, 14: 300–306.
69. Oiso N, Riddle SR, Serikawa T, Kuramoto T, Spritz RA: The rat Ruby (R)
locus is Rab38: identical mutations in Fawn-hooded and Tester-Moriyama
rats derived from an ancestral Long Evans rat sub-strain. Mamm Genome.,
2004, 15: 307–314.
70. Suzuki T, Ito S, Inagaki K, Suzuki N, Tomita Y, Yoshino M, Hashimoto T:
Investigation on the IVS5 +5G ] A splice site mutation of HPS1 gene found in
Japanese patients with Hermansky-Pudlak syndrome. J Dermatol Sci., 2004,
36: 106–108.
71. Nguyen T, Wei ML: Characterization of melanosomes in murine Hermansky-
Pudlak syndrome:mechanisms of hypopigmentation. J Invest Dermatol.,
2004, 122: 452–460.
72.Feng L, Novak EK, Hartnell LM, Bonifacino JS, Collinson LM, Swank RT: The
Hermansky-Pudlak syndrome 1 (HPS1) and HPS2 genes independently
contribute to the production and function of platelet dense granules,
melanosomes, and lysosomes. Blood, 2002, 99:1651–1658.
73.Gardner JM, Wildenberg SC, Keiper NM, Novak EK, Rusiniak ME, Swank RT,
Puri N, Finger JN, Hagiwara N, Lehman AL, Gales TL, Bayer ME, King RA,
Brilliant MH: The mouse pale ear (ep) mutation is the homologue of human
Hermansky-Pudlak syndrome. Proc Natl Acad Sci USA, 1997; 94: 9238–
9243.
74. Li W, Zhang Q, Oiso N, Novak EK, Gautam R, O’Brien EP, Tinsley CL, et al:
Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a
member of the biogenesis of lysosome-related organelles complex 1 (BLOC-
1). Nat Genet., 2003, 35: 84–89.
75. Wei Li, Michael E. Rusiniak, Sreenivasulu Chintala, Rashi Gautam, Edward
K. Novak, and Richard T. Swank. Murine Hermansky–Pudlak syndrome
genes: regulators of lysosome-related organelles. Bio Essays, Volume 26, (6)
616-628.
76. Santiago M. Di Pietro, Juan M. Falco´n-Pe´rez, Danie`le Tenza, Subba R.G.
Setty, Michael S. Marks, Grac¸a Raposo, and Esteban C. Dell’Angelica.
BLOC-1 Interacts with BLOC-2 and the AP-3 Complex to Facilitate Protein
Trafficking on Endosomes. Molecular Biology of the Cell, 2006, Vol. 17,
4027–4038.
77. Subba Rao Gangi Setty, Danièle Tenza, Steven T. Truschel, Evelyn Chou,
Elena V. Sviderskaya, Alexander C. Theos, M. Lynn Lamoreux, Santiago M.
Di Pietro, Marta Starcevic, Dorothy C. Bennett, Esteban C. Dell’Angelica,
References 101
Grac¸a Raposo, and Michael S. Marks. BLOC-1 Is Required for Cargo-
specific Sorting from Vacuolar Early Endosomes toward Lysosome-related
Organelles. Molecular Biology of the Cell, 2007, Vol. 18, 768–780.
78. Santiago M. Di Pietro, Juan M. Falco´ n-Pe´ rez and Esteban C.
Dell’Angelica. Characterization of BLOC-2, a Complex Containing the
Hermansky–Pudlak Syndrome Proteins HPS3, HPS5 and HPS6. Traffic,
2004, 5: 276–283.
79. Juan S. Bonifacino. Insights into the Biogenesis of Lysosome-Related
Organelles from the Study of the Hermansky-Pudlak Syndrome. Ann. N.Y.
Acad. Sci., 2004, 1038: 103–114.
80. Rashi Gautam, Edward K. Novak, Jian Tan, Kazumasa Wakamatsu,
Shosuke Ito and Richard T. Swank1 Interaction of Hermansky-Pudlak
Syndrome Genes in the Regu. of Lysosome-Related Organelles. Traffic,
2006, 7: 779–792.
81. Marta Starcevic, Ramin Nazarian and Esteban C. Dell’Angelica. The
molecular machinery for the biogenesis of lysosome-related organelles:
lessons from Hermansky–Pudlak syndrome. Seminars in Cell &
Developmental Biology, 2002, Vol. 13,pp. 271–278.
82.Li, W. et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant
dysbindin, a member of the biogenesis of lysosome-related organelles
complex 1 (BLOC-1). Nat. Genet., 2003, 35, 84–89.
83.Gwynn, B. et al. (2004). Reduced pigmentation (rp), a mouse model of
Hermansky-Pudlak syndrome, encodes a novel component of the BLOC-1
complex. Blood, 2004, 104, 3181–3189.
84.Moriyama, K., and Bonifacino, J. S. Pallidin is a component of a multi-protein
complex involved in the biogenesis of lysosome-related organelles. Traffic,
2002, 3, 666–677.
85.Ciciotte, S. L., Gwynn, B., Moriyama, K., Huizing, M., Gahl, W. A., Bonifacino,
J. S., and Peters, L. L. Cappuccino, a mouse model of Hermansky-Pudlak
syndrome, encodes a novel protein that is part of the pallidin-muted complex
(BLOC-1). Blood, 2003, 101, 4402–4407.
86.Gautam, R., Chintala, S., Li, W., Zhang, Q., Tan, J., Novak, E. K., Di Pietro,
S. M., Dell’Angelica, E. C., and Swank, R. T. The Hermansky-Pudlak
syndrome 3 (cocoa) protein is a component of the biogenesis of
lysosomerelated organelles complex-2 (BLOC-2). J. Biol. Chem., 2004, 279,
12935–12942.
87.Qing Zhang, Baohui Zhao, Wei Li, Naoki Oiso, Edward K. Novak, Michael E.
Rusiniak, Rashi Gautam, Sreenivasulu Chintala, Edward P. O'Brien, Yuke
References 102
Zhang, Bruce A. Roe, Rosemary W. Elliott, Eva M. Eicher, Ping Liang,
Christian Kratz, Eric Legius, Richard A. Spritz, T. Norene O'Sullivan, Neal G.
Copeland, Nancy A. Jenkins & Richard T. Swank. Ru2 and Ru encode
mouse orthologs of the genes mutated in human Hermansky-Pudlak
syndrome types 5 and 6. Nature Genetics, 2003, 33, 145 – 153.
88.GH Feng, T Bailin, J Oh and RA Spritz . Mouse pale ear (ep) is homologous
to human Hermansky-Pudlak syndrome and contains a rare ‘AT-AC’ intron.
Human Molecular Genetics, Vol 6, 793-797.
89.Tamio Suzuki, Wei Li, Qing Zhang, Amna Karim, Edward K. Novak, Elena V.
Sviderskaya, Simon P. Hill, Dorothy C. Bennett, Alex V. Levin, H. Karel
Nieuwenhuis, Chin-To Fong, Claudio Castellan, Bianca Miterski, Richard T.
Swank & Richard A. Spritz. Hermansky-Pudlak syndrome is caused by
mutations in HPS4, the human homolog of the mouse light-ear gene. Nature
Genetics, 2002, 30, 321-324.
90.Juan M. Falcón-Pérez, Marta Starcevic, Rashi Gautam, and Esteban C.
Dell'Angelica. BLOC-1, a Novel Complex Containing the Pallidin and Muted
Proteins Involved in the Biogenesis of Melanosomes and Platelet-dense
Granules. J. Biol. Chem., 2002, Vol. 277, Issue 31, 28191-28199..
91.Juan M. Falcón-Pérez, Ramin Nazarian, Chiara Sabatti, and Esteban C.
Dell'Angelica. Distribution and dynamics of Lamp1-containing endocytic
organelles in fibroblasts deficient in BLOC-3. Journal of Cell Science, 2005,
118, 5243-5255.
92. Esteban C Dell’Angelica. The building BLOC(k)s of lysosomes and related
organelles. Current Opinion in Cell Biology, 2004, 16:458–464.
93. Greg Odorizzi, Christopher R. Cowles and Scott D. Emr The AP-3 complex:
a coat of many colours. Trends in cell biology, 1998, Volume 8, Issue 7, 282-
288.
94.Fiona Simpson, Andrew A. Peden, Lina Christopoulou, Margaret S. Robinson.
Characterization of the Adaptor-related protein complex, AP-3. The Journal of
Cell Biology, 1997, Volume 137, 835-845.
95. Kantheti P, Qiao X, Diaz ME, Peden AA, Meyer GE, Carskadon SL,
Kapfhamer D, Sufalko D, Robinson MS, Noebels JL, and Burmeister M.
Mutation in AP-3 delta in the mocha mouse links endosomal transport to
storage deficiency in platelets, melanosomes and synaptic vesicles. Neuron,
1998, 21: 111-122.
96. Timothy A. Lyerla, Michael E. Rusiniak, Michael Borchers, Gerald Jahreis,
Jian Tan, Patricia Ohtake, Edward K. Novak, and Richard T. Swank. Aberrant
lung structure, composition, and function in a murine model of Hermansky-
References 103
Pudlak syndrome. Am J Physiol Lung Cell Mol Physiol., 2003, 285: L643-
L653.
97.Santiago M. Di Pietro, Juan M. Falcón-Pérez, Danièle Tenza , Subba R.G.
Setty, Michael S. Marks, Graça Raposo, and Esteban C. Dell’Angelica.
BLOC-1 interacts with BLOC-2 and the AP-3 complex to facilitate protein
trafficking on endosomes. Molecular Biology of the Cell, 2006, Vol. 17, Issue
9, 4027-4038.
98.Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H,
Calis KA, Gochuico B: Effect of pirfenidone on the pulmonary fibrosis of
Hermansky-Pudlak syndrome. Mol Genet Metab., 2002, 76: 234–242.
99. Huizing M, Gahl WA: Disorders of vesicles of lysosomal lineage: the
Hermansky-Pudlak syndromes. Curr Mol Med., 2002, 2: 451–467.
100. Anderson PD, Huizing M, Claassen DA, White J, Gahl WA: Hermansky-
Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. Hum
Genet., 2003, 113: 10–17.
101. Maria L. Wei. Hermansky-Pudlak syndrome: a disease of protein
trafficking and organelle function. Pigment Cell Res., 2006, 19:19-42.
102. Lijun Feng, Brian W. Rigatti, Edward K. Novak, Michael B. Gorin and
Richard T. Swank. Genomic Structure of the Mouse Ap3b1 Gene in Normal
and Pearl Mice. Genomics, 2000, Volume 69, Issue 3, 370-379.
103. Andrew A. Peden, Rachel E. Rudge, Winnie W.Y. Lui and Margaret S.
Robinson. Assembly and function of AP-3 complexes in cells expressing
mutant subunits. The Journal of Cell Biology, 2002, Volume 156, Number 2,
327-336.
104. MP McGarry, M Reddington, EK Novak and RT Swank. Survival and lung
pathology of mouse models of Hermansky-Pudlak syndrome and Chediak-
Higashi syndrome. Proceedings of the Society for Experimental Biology and
Medicine, 2003, Vol 220, 162-168.
105. Wixler V., Laplantine E., Geerts D., Sonnenberg A., Petersohn D., Eckes
B., Paulsson M., Aumailley M. Identification of novel interaction partners for
the conserved membrane proximal region of α-integrin cytoplasmic domains.
FEBS Letters,1999, Volume 445, Number 2, 351-355(5).
106. Susan H. Guttentag, Amana Akhtar, Jian-Qin Tao, Elena Atochina,
Michael E. Rusiniak, Richard T. Swank, and Sandra R. Bates. Defective
Surfactant Secretion in a Mouse Model of Hermansky-Pudlak Syndrome. Am
J Respir Cell Mol Biol., 2005, Vol 33; 14–21.
References 104
107. Cheng-Lun Na, ChenXia Duan, Karen S. Apsley and Timothy E. Weaver.
Abnormal alveolar type 2 cell phenotype in AP-3 Mutant Mocha and Pearl
mice: an electron microscopy study. Microsc Microanal., 2003, 9:1426–1427.
108. Dell’Angelica EC, Augilar RC, Wolins N, Hazelwood S, Gahl WA,
Bonifacino JS. Molecular characterization of the protein encoded by the
Hermansky-Pudlak syndrome type 1 gene. J Biol Chem., 2000, 275:1300-
1306.
109. Karen Newell-Litwa, Eunju Seong, Margit Burmeister and Victor Faundez.
Neuronal and non-neuronal functions of the AP-3 sorting machinery. Journal
of Cell Science, 2007, 120; 531-541.
110. Chean Eng Ooi, Esteban C.Dell’ Angelica and Juan S.Bonifacino. ADP-
Ribosylation Factor 1 (ARF1) regulates recruitment of the AP-3 adaptor
complex to membranes.The Journal of Cell Biology, 1998, Vol 142; 391-402.
111. Bjoern Chapuy, Ritva Tikkanen, Chris Muehlhausen, Dirk Wenzel, Kurt
von Figura and Stefan Hoening. AP-1 and AP-3 Mediate Sorting of
Melanosomal and Lysosomal Membrane Proteins into Distinct Post-Golgi
Trafficking Pathways. Traffic, 2008; 9: 1157–1172.
112. Harrison-Lavoie KJ, Michaux G, Hewlett L, Kaur J, Hannah MJ, Lui-
Roberts WW, Norman KE, Cutler DF. P-selectin and CD63 use different
mechanisms for delivery to Weibel-Palade bodies. Traffic, 2006 Jun;7(6):647-
62.
113. Daugherty BL, Straley KS, Sanders JM, Phillips JW, Disdier M, McEver
RP, Green SA. AP-3 adaptor functions in targeting P-selectin to secretory
granules in endothelial cells. Traffic, 2001 Jun;2(6):406-13.
114. Gundrun Inrke, Aija Kyttaala, Matthew R.G. Russell, Brian A. Rous and J.
Paul Luzio. Differential use of two AP-3 mediated pathways by lysosomal
membrane proteins. Traffic, 2004, 5; 946-962.
115. Brian A. Rous, Barbara J. Reaves, Gudrun Ihrke, John A.G. Briggs, Sally
R.Gray, David J. Stephens, George Banting, and J. Paul Luzio. Role of
Adaptor Complex AP-3 in Targeting Wild-Type and Mutated CD63 to
Lysosomes. Molecular Biology of the Cell, 2002, Vol. 13, 1071–1082, March.
116. Dell’Angelica EC, Augilar RC, Wolins N, Hazelwood S, Gahl WA,
Bonifacino JS. Molecular characterization of the protein encoded by the
Hermansky-Pudlak syndrome type 1 gene. J Biol Chem., 2000, 275:1300-
1306.
117. Clark, R.H. and Stinchcombe, J.C. and Day, A. and Blott, E. and Booth, S.
and Bossi, G. and Hamblin, T. and Davies, E.G. and Griffiths, G.M. Adaptor
protein 3–dependent microtubule-mediated movement of lytic granules to the
References 105
immunological synapse. Nature Immunology, 2003, 4 (11). pp. 1111-1120.
ISSN 15292908.
118. John L. Prueitt, Emil Y. Chi, and David Lagunoff. Pulmonary surface-
active materials in the Chediak-Higashi syndrome. Journal of Lipid Research,
1978, Volume 19.
119. Kazuhiro Osanai, Rieko Oikawa, Junko Higuchi, Makoto Kobayashi,
Katsuma Tsuchihara, Masaharu Iguchi, Huang Jongsu, Hirohisa Toga and
Dennis R. Voelker. A Mutation in Rab38 Small GTPase Causes Abnormal
Lung Surfactant Homeostasis and Aberrant Alveolar Structure in Mice.
American Journal of Pathology, 2008, 173:1265-1274.
120. S. Palmeri, P. Tarugi, F. Sicurelli, R. Buccoliero, A. Malandrini, M.M. De
Santi, G. Marcianò C. Battisti, M.T. Dotti, S. Calandra, A. Federico. Lung
involvement in Niemann-Pick disease type C1: improvement with
bronchoalveolar lavage. Neurol Sci., 2005, 26:171–173.
121. Margaret M. McGovern, Melissa P. Wasserstein, Roberto Giugliani,
Bruno Bembi, Marie T. Vanier, Eugen Mengel, Scott E. Brodie, David
Mendelson, Gwen Skloot, Robert J. Desnick, Noriko Kuriyama, MAj, Gerald
F. Cox. A Prospective, Cross-sectional Survey Study of the Natural History of
Niemann-Pick Disease Type B. Pediatrics, 2008, 122:e341–e349.
122. Björn Bjurulf, Signe Spetalen, Aage Erichsen, Marie T. Vanier, Erik H.
Strom, Petter Stromme. Niemann-Pick disease type C2 presenting as fatal
pulmonary alveolar lipoproteinosis: Morphological findings in lung and
nervous tissue. Med Sci Monit., 2008, 14(8): CS71-75.
123. Buccoliero R, Ginzburg L, Futerman AH. Elevation of lung surfactant
phosphatidylcholine in mouse models of Sandhoff and Niemann-Pick disease.
J Inher Metab Dis., 2004, 27:641–648.
124. Rajwinder Dhami, Xingxuan He, Ronald E Gordon and Edward H
Schuchman. Analysis of the Lung Pathology and Alveolar Macrophage
Function in the Acid Sphingomyelinase–Deficient Mouse Model of Niemann-
Pick Disease. Lab Invest., 2001, 81:987–999.
125. Amin RS, Wert SE, Baughman RP, Tomashefski JF, Nogee LM, Brody
AS. Surfactant protein deficiency in familial interstitial lung disease. Journal of
Pediatrics, 2001, 139:85-92.
126. Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA: A
mutation in the surfactant protein C gene associated with familial interstitial
lung disease. New England Journal of Medicine 2001, 344:573-579.
References 106
127. Stillwell PC, Norris DG, Oconnell EJ, Rosenow EC, Weiland LH, Harrison
EG: Desquamative Interstitial Pneumonitis in Children. Chest, 1980, 77:165-
171.
128. King TE: Diagnostic Advances in Idiopathic Pulmonary Fibrosis. Chest
1991, 100:238-241.
129. Surafel Mulugeta, Vu Nguyen, Scott J. Russo, Madesh Muniswamy and
Michael F. Beers. A Surfactant Protein C Precursor Protein BRICHOS
Domain Mutation Causes Endoplasmic Reticulum Stress, Proteasome
Dysfunction, and Caspase 3 Activation. American Journal of Respiratory Cell
and Molecular Biology, 2005, Vol. 32, pp. 521-530.
130. Glasser SW, Detmer EA, Ikegami M, Na CL, Stahlman MT, Whitsett JA:
Pneumonitis and emphysema in SP-C gene targeted mice. J Biol Chem.,
2003, 278:14291-14298.
131. Sergey Shulenin, Ph.D., Lawrence M. Nogee, M.D., Tarmo Annilo, Ph.D.,
Susan E. Wert, Jeffrey A. Whitsett, and Michael Dean. ABCA3 Gene
Mutations in Newborns with Fatal Surfactant Deficiency. N Engl J Med., 2004,
350; 1296-303.
132. Janine E. Bullard, Susan E. Wert, Jeffrey A. Whitsett, Michael Dean, and
Lawrence M. Nogee. ABCA3 Mutations Associated with Pediatric Interstitial
Lung. Am J Respir Crit Care Med., 2005, October 15; 172(8): 1026–1031.
133. Christiane Albrecht, Enrique Viturro. The ABCA subfamily—gene and
protein structures, functions and associated hereditary diseases. Pflugers
Arch - Eur J Physiol., 2007, 453: 581–589.
134. Lisa R. Young, Lawrence M. Nogee, Bruce Barnett, Ralph J. Panos,
Thomas V. Colby, and Gail H. Deutsch. Usual Interstitial Pneumonia in an
Adolescent with ABCA3 Mutations. Chest, 2008; 134:192-195.
135. Esteban C. Dell’Angelica, Chris Mullins, Steve Caplan, and Juan S.
Bonifacino. Lysosome related organelles. The FASEB Journal, 2000,
14:1265-1278.
136. Lijun Feng, Edward K. Novak, Lisa M. Hartnell, Juan S. Bonifacino, Lucy
M. Collinson and Richard T. Swank. The Hermansky-Pudlak syndrome 1
(HPS1) and HPS2 genes independently contribute to the production and
function of platelet dense granules. Blood, 2002, 99: 1651-1658.
137. Katarina Kaedgal, Uno Johansson and Karin Oellinger. The lysosomal
protease cathepsin D mediates apoptosis induced by oxidative stress.
FASEB, 2001, Vol. 15, 1592-1594.
References 107
138. Heidi K. Baumgartner, Julia V. Gerasimenko, Christopher Thorne, Louise
H. Ashurst, Stephanie L. Barrow, Michael A. Chvanov, Stuart Gillies, David N.
Criddle, Alexei V. Tepikin, Ole H. Petersen, Robert Sutton, Alastair J. M.
Watson, and Oleg V. Gerasimenko. Caspase-8-mediated apoptosis induced
by oxidative stress is independent of the intrinsic pathway and dependent on
cathepsins. Am J Physiol., 2007, 293: G296.
139. Xiaopeng Li, Heather Rayford, Ruijie Shu, Jiaju Zhuang, and Bruce D.
Uhal. Essential role for cathepsin D in bleomycin-induced apoptosis of
alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol, 2004, 287: L46–
L51.
140. B.D. Uhal. Epithelial apoptosis in the initiation of lung fibrosis. Eur Respir
J, 2003, 22:7s-9s.
141. Alina Minarowska, Lukasz Miarowski, Alicja Karwowska, Marek Gacko.
Regulatory role of cathepsin D in apoptosis. Folia Histochemica ET
Cytobiologica, 2007, Vol. 45, No. 3, 2007 pp. 159-163.
142. Roberta Castino, Natascia Bellio, Giuseppina Nicotra, Carlo Follo, Nicol F.
Trincheri, Ciro Isidoro Cathepsin D–Bax death pathway in oxidative stressed
neuroblastoma cells. Free Radical Biology & Medicine 42, 2007, 1305–1316.
143. Robert Blomgran, Limin Zheng, and Olle Stendahl. Cathepsin-cleaved Bid
promotes apoptosis in human neutrophils via oxidative stress-induced
lysosomal membrane permeabilization J Leukoc Biol., 2007, 81: 1213–1223.
144. ALberts, Johnson, Lewis, Raff, Roberts, Walter. Molecular biology of the
cell. ISBN 0-8153-3218-1.
145. Stefan J. Marciniak and David Ron. Endoplasmic Reticulum Stress
Signaling in Disease. Physiol., 2006, Rev. 86: 1133-1149, doi: 10.1152 /
physrev.00015.2006.
146. Yoshida H. ER stress and diseases. Febs J., 2007, 274: 630-658.
147. Jianze Li, Brenda Lee, and Amy S. Lee. Endoplasmic reticulum-stress
induced apoptosis: Multiple pathways and activation of PUMA and NOXA by
p53. J. Biol. Cehm., 2006, 17;281(11):7260-70.
148. S.Oyadomari, and M Mori. Roles of CHOP/GADD153 in endoplasmic
reticulum Stress. Cell Death and Differentiation, 2004, 11, 381–389.
149. Remotti, James L. Stevens and David Ron Helene Zinszner, Masahiko
Kuroda, XiaoZhong Wang, Nikoleta Batchvarova, Richard T. Lightfoot, Helen.
CHOP is implicated in programmed cell death in response to impaired
function of the endoplasmic reticulum. Genes & Dev, 1998, 12: 982-995.
References 108
150. Wang XZ, Lawson B, Brewer JW, Zinszner H, Sanjay A, Mi LJ, Boorstein
R, Kreibich G, Hendershot LM and Ron D. Signals from the stressed
endoplasmic reticulum induce C/EBP-homologous protein (CHOP/
GADD153). Mol. Cell. Biol., 1996, 16: 4273–4280.
151. Oyadomari S, Takeda K, Takiguchi M, Gotoh T, Matsumoto M, Wada I,
Akira S, Araki E and Mori M. Nitric oxide-induced apoptosis in pancreatic beta
cells is mediated by the endoplasmic reticulum stress pathway. Proc. Natl.
Acad. Sci., 2001, 98: 10845–10850.
152. Endo M, Oyadomari S, Suga M, Mori M, and Gotoh T. The ER stress
pathway involving CHOP is activated in the lungs of LPS-treated mice. J
Biochem (Tokyo), 2005, 138: 501-507.
153. Yoshida H. ER stress and diseases. Febs J., 2007, 274: 630-658.
154. Surafel Mulugeta, Vu Nguyen, Scott J. Russo, Madesh Muniswamy and
Michael F. Beers. A Surfactant Protein C Precursor Protein BRICHOS
Domain Mutation Causes Endoplasmic Reticulum Stress, Proteasome
Dysfunction, and Caspase 3 Activation. American Journal of Respiratory Cell
and Molecular Biology, 2005, Vol. 32, pp. 521-530.
155. Martina Korfei, Clemens Ruppert, Poornima Mahavadi, Ingrid Henneke,
Philipp Markart, Miriam Koch, Gyoergy Lang, Ludger Fink, Rainer-Maria
Bohle, Werner Seeger, Timothy E. Weaver and Andreas Guenther. Epithelial
endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary
fibrosis. Am. J. Respir. Crit.Care. Med., 2008, Vol.178; 00838-846.
156. Alexander C. Theos, Joanne F. Berson, Sarah C. Theos, Kathryn E.
Herman, Dawn C. Harper, Danie`le Tenza, Elena V. Sviderskaya, M. Lynn
Lamoreux, Dorothy C. Bennett, Grac¸a Raposo, and Michael S. Marks. Dual
Loss of ER Export and Endocytic Signals with Altered Melanosome
Morphology in the silver Mutation of Pmel17. Molecular Biology of the Cell,
2006, Vol. 17, 3598–3612.
157. A d’Azzo, A Tessitore and R Sano. Gangliosides as apoptotic signals in
ER stress response Cell Death and Differentiation, 2006, 13, 404–414.
158. Alessandra Tessitore, Maria Del.P.Martin, Renata Sano, Yanjun Ma, Linda
Mann, Angela Ingrassia, Eric D.Laywell, Dennis A.Steindler, Linda
M.Hendershot and Alessendara d’Azzo. GM1-Ganglioside-mediated activation
of the unfolded protein response causes neuronal death in a
neurodegenerative Gangliosidosis. Molecular Cell, 2004, Vol.15, 753-766.
159. Sophie Degroote, Jasja Wolthoorn, Gerrit van Meer. The cell biology of
glycosphingolipids. Seminars in Cell and Developmental Biology, 2004, 15:
375-387.
References 109
160. M. Elleder. Glucosylceramide transfer from lysosomes—the missing link in
molecular pathology of glucosylceramidase deficiency: A hypothesis based
on existing data. J Inherit Metab Dis., 2006, 29:707–715.
161. Lisa R. Young, Michael T. Borchers, Holly L. Allen, Reta S. Gibbons, and
Francis X. McCormack. Lung-Restricted Macrophage Activation in the Pearl
Mouse Model of Hermansky-Pudlak Syndrome. The Journal of Immunology,
2006, 176: 4361–4368.
162. Lisa R. Young, Rajamouli Pasula, Peter M. Gulleman, Gail H. Deutsch
and Francis X. McCormack. Susceptibility of Hermansky-Pudlak Mice to
Bleomycin-Induced Type II Cell Apoptosis and Fibrosis. American Journal of
Respiratory Cell and Molecular Biology, 2007, Vol. 37, pp. 67-74.
163. Judit E Pongracz and Robert A Stockley. Wnt signalling in lung
development and diseases. Respiratory Research, 2006, 7:15.
164. Melanie Koenigshoff, Nisha Balsara, Eva-Maria Pfaff, Monika Kramer,
Izabella Chrobak, Werner Seeger, Oliver Eickelberg. Functional Wnt
Signaling Is Increased in Idiopathic Pulmonary Fibrosis. PLoS ONE, 2008,
Volume 3, Issue 5, e2142.
165. Minhong Yan and Greg D. Plowman. Delta-like 4/Notch Signaling and
ItsTherapeutic Implications. Clin Cancer Res., 2007, 13(7243 24).
166. Biao Hu, Tianju Liu, Zhe Wu, and Sem H. Phan. Notch regulation of
telomerase induction in pulmonary fibrosis. FASEB J., 2008, 22:596.1
[Meeting Abstract]
167. Anna Serrano-Mollar, Maria Nacher, Gemma Gay-Jordi, Daniel Closa,
Antoni Xaubet, and Oriol Bulbena. Intratracheal Transplantation of Alveolar
Type II Cells Reverses Bleomycin-induced Lung Fibrosis. Am J Respir Crit
Care Med., 2007, Vol 176. pp 1261–1268.
168. James P. Bridges,1 Yan Xu,1 Cheng-Lun Na,1 Hector R. Wong,2 and
Timothy E. Weaver. Adaptation and increased susceptibility to infection
associated with constitutive expression of misfolded SP-C. The Journal of
Cell Biology, Vol. 172, No. 3, January 30, 2006 395–407.
169. Apoptosis and necrosis induced by cyclic mechanical stretching in alveolar
type-II-cells--influence of captopril and L-Arginine. Hammerschmidt S, Kuhn
H, Grasenack T, Gessner C, Wirtz H. Pneumologie, 2004, 58(4): 222-9.
170. Immunolocalization of cathepsin D in pneumocytes of normal human lung
and in pulmonary fibrosis. M. Kasper, M. Haase, D. Schuh, M. Müller and
P. Lackie. Virchows archives, 1996, Volume 428, Numbers 4-5.
Acknowledgements 110
Acknowledgements
My first and foremost acknowledgement goes to my principle investigator, Prof. Dr.
Andreas Guenther. I am greatly indebted to him for his immense belief in me and his all
time support and encouragement during the bad and good times of my PhD career. I
have started my research career in his lab and it is only because of his able guidance,
that I have reached this phase of my PhD career. “Thank you” is a very small word to
extend my gratitude to Andreas.
I extend my sincere gratitude to Prof. Dr. Michael Martin who readily agreed to be my
co-principle investigator and who guided me through the process of obtaining my PhD.
I sincerely thank Prof. Dr. Gerd Schmitz and Dr. Gerhard Liebisch, without whose co-
operation, the lipidomics study would not have been possible.
I would like to extend my sincere thanks to the “Molecular Biology Medicine of the Lung”
International Graduate Program, where I have learnt the essence of science. I would
like to extend my sincere gratitude to Prof. Dr. Werner Seeger for giving me the
opportunity of learning science in an international atmosphere.
I would like to thank Dr. Martina Korfei, who is more a friend than my post-Doc and from
whom I have learnt the fine aspects of research. I always appreciate her immence
guidance during my PhD work. I sincerely thank Dr. Clemens Ruppert, for excellently
handling and managing all the HPS mice and for all his patience to answer all my
questions . His technical guidance has always been immensely useful.
I would like to thank Ingrid Henneke for extending all her help in my animal experiments.
I thank my lab technicians, Silke Haendel and Juliane Mest for their all time help. My
sincere thanks to Dr. Karin Endris, from whom I received unforgettable help in
administrative issues.
My husband always stood by me with a lot of patience, understanding and caring. He is
my twin soul and his constant support and encouragement have helped me althrough
my career. Mummy and nana (my parents) have always been my pillars of support. I
dedicate my thesis to my parents and it goes without saying that my mom, dad and my
brother, ever deserve my deepest gratitude.
Anhang 111
Anhang
Publications
1. Markart. P, Luboeinski. T, Korfei. M, Schmidt. R, Wygrecka. M, Mahavadi. P, Mayer
K, Wilhelm J, Seeger. W, Guenther. A, Ruppert. C. Alveolar oxidative stress is
associated with elevated levels of non-enzymatic low-molecular-weight antioxidants
in patients with different forms of chronic fibrosing interstitial lung diseases. Antioxid
Redox Signal (2009)11(2):227-40
2. Korfei. M, Ruppert. C, Mahavadi. P, Henneke. I, Markart. P, Koch. M, Lang. G, Fink.
L, Bohle. RM, Seeger. W, Weaver. TE, Guenther. A. Epithelial endoplasmic
reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J
Respir Crit Care Med., (2008) 15;178(8):838-46.
3. Ruppert C, Mahavadi P, Wygrecka M, Magdolen V, Idell S, Preissner K.T,
Seeger.W, Guenther.A, Markart.P. Recombinant production of a hybrid plasminogen
activator composed of surfactant protein B and low-molecular weight urokinase.
Thrombosis and Haemostasis (2008)100(6):1185-92.
Oral presentations
1. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Liebisch. G, Schmitz. G, Bernadette.
G, Seeger. W., and Guenther. A. Evidence of Surfactant Accumulation and Type II
Pneumocyte Apoptosis in Hermansky Pudlak Syndrome Associated Lung Fibrosis.
American Thoracic Society, Toronto, Canada, 16-21 May, 2008.
2. Mahavadi P, Schwertner. L., Mokry. T, Henneke. I, Korfei. M, Seeger. W, Guenther.
W, Ruppert C. Surfactant Alterations and Lung Fibrosis in a Murine Model of
Amiodarone-Induced Pulmonary Fibrosis. Herbst treffen, Section Zell Biologie -
Deutsche Gesselschaft fur Pneumologie, Munchen, Germany, November, 2007.
3. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Seeger. W, and Guenther. A.
Impaired lysosomal trafficking and epithelial apoptosis in a murine model of
Hermansky-Pudlak-Syndrome. MBML annual retreat, Rauischholzhausen, Germany,
31 July- 2 August 2006.
4. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Seeger. W, and Guenther. A.
Impaired lysosomal trafficking in a murine model of Hermansky-Pudlak-Syndrome.
Kongress der Deutsche Gesselschaft fur Pneumologie und Beatmungsmedizin,
Nurnberg, Germany, 29 March – 1 April, 2006.
5. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Seeger. W, and Guenther. A.
Altered surfactant metabolism in a murine model of Hermansky-Pudlak syndrome.
Herbst treffen, Section Zell Biologie - Deutsche Gesselschaft fur Pneumologie,Bonn,
Germany, October, 2005.
Anhang 112
6. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Seeger. W, and Guenther. A.
Surfactant alterations trafficking in a murine model of Hermansky-Pudlak-Syndrome.
MBML annual retreat, Rauischholzhausen, Germany, 1- 3 August 2005.
Poster presentations
1. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Liebisch. G, Schmitz. G, Bernadette.
G, Seeger. W., and Guenther. A. Role of impaired lysosomal trafficking in a murine
model of Hermansky-Pudlak-syndrome associated interstitial pneumonia (HPSIP).
Herbst treffen, Section Zell Biologie - Deutsche Gesselschaft fur
Pneumologie,Freiburg, Germany, 08-08 November, 2008
2. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Liebisch. G, Schmitz. G, Bernadette.
G, Weaver. T, Seeger. W., and Guenther. A. Evidence of type II pneumocyte
apoptosis and lung fibrosis in murine Hermansky-Pudlak-Syndrome associated
interstitial pneumonia (HPSIP). European Respiratory Society, Berlin, Germany, 4-8
October, 2008.
3. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Liebisch. G, Schmitz. G, Bernadette.
G, Weaver. T, Seeger. W., and Guenther. A. Role of impaired lysosomal trafficking
and epithelial apoptosis in a murine model of Hermansky-Pudlak-Syndrome
associated Interstitial Pneumonia (HPSIP). International colloquium for airway and
lung fibrosis, North Carolina, USA, 28 September to 01 October, 2008.
4. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Liebisch. G, Schmitz. G, Bernadette.
G, Weaver. T, Seeger. W., and Guenther. A. Extensive intracellular accumulation of
surfactant phospholipids and proteins underlies development of epithelial stress,
apoptosis and lung fibrosis in murine Hermansky Pudlak Syndrome 1/2. Leopoldina
Symposium on Lipid Signalling, Frankfurt, Germany, 4-7 September, 2008.
5. Mahavadi P, Schwertner. L., Mokry. T, Henneke. I, Korfei. M, Seeger. W, Guenther.
W, Ruppert C. Surfactant Alterations and Lung Fibrosis in a Murine Model of
Amiodarone-Induced Pulmonary Fibrosis. American Thoracic Society, Toronto,
Canada, 16-21 May, 2008.
6. Mahavadi P, Schwertner. L., Mokry. T, Henneke. I, Korfei. M, Seeger. W, Guenther.
W, Ruppert C. Surfactant Alterations and Lung Fibrosis in a Murine Model of
Amiodarone-Induced Pulmonary Fibrosis. Kongress der Deutsche Gesselschaft fur
Pneumologie und Beatmungsmedizin, Luebeck, Germany. 9-12 April, 2008.
7. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Seeger. W, and Guenther. A. Role
of impaired lysosomal trafficking and epithelial apoptosis in a murine model of
Hermansky-Pudlak-Syndrome associated Interstitial Pneumonia (HPSIP).
International Colloquium on Lung Fibrosis, Reinhartshausen, Germany, 7-10
September 2006.
Anhang 113
8. Mahavadi. P, Korfei. M, Ruppert. C Henneke. I, Seeger.W, and Guenther. A. Role of
impaired lysosomal trafficking and epithelial apoptosis in a murine model of
Hermansky-Pudlak-Syndrome associated Interstitial Pneumonia (HPSIP). American
Thoracic Society, San Diego, USA, 18-23 May 2006.
